Published in final edited form as:

Chem Rev. 2007 November ; 107(11): 5065–5081. doi:10.1021/cr068221w.

Substrate and Docking Interactions in Ser/Thr Protein Kinases

Elizabeth J. Goldsmith^{1,*}, Radha Akella¹, Xiaoshan Min², Tianjun Zhou³, and John M. Humphreys¹

¹Department of Biochemistry, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75390-8816

²Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799

³Ariad Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, MA 02139-4234

1. Introduction

Protein kinases have emerged as the largest family of signaling proteins in eukaryotic cells and are involved in every aspect of cellular regulation. There are over 500 protein kinases in the human genome.^{1,2} The vast majority are Ser/Thr protein kinases. The Ser/Thr protein kinases interact with diverse substrates ranging from enzymes, including other kinases, to transcription factors, receptors, and other regulatory proteins. Thus, mechanisms to assure specificity must be present. However, from emerging structural data it is becoming apparent that the ways in which protein kinases interact with their substrates local to the active site are relatively few. Instead, docking interactions, in pockets or grooves outside the active site of the kinase, are used to recognize substrates and other interacting proteins. Docking motifs in substrates bind in docking grooves within the kinase domain or adaptor protein. Docking interactions have been defined for CDKs (cyclin dependent kinases), MAPKs (mitogen activated protein kinases), and members of the AGC group (cAMP-dependent (PKA), cGMP-dependent, PKC), as well as several other kinases. Further, structural data is revealing that docking interactions regulate kinase activity by unanticipated allosteric mechanisms that probably promote pathway specificity.

In this review, we outline the current structural data available on distinct Ser/Thr protein kinases. How kinases bind substrates at the active site is described, focusing on the P+1 pocket, which is remodeled in inactive forms of several protein kinases. Substrate docking interactions, outside the active site, observed in MAP kinases, CDKs and AGC kinases will be described. How specificity among these different families of kinases is achieved from the organization of the binding site and other factors will be discussed. Further, available data suggesting that docking interactions control kinase activity allosterically will be reviewed. Recent reviews of topics under discussion,^{3–10} and related topics^{11–17} are available.

*Corresponding Author Elizabeth.Goldsmith@UTSouthwestern.edu, Phone (214) 645-6376, FAX (214) 645-6387.

2. Architecture and Available Structural Data

Among eukaryotic protein kinases,¹ the Ser/Thr kinases have been classified into six large groups. These are named the AGC group, the CaMK group (for calcium-calmodulin dependent), the CMGC group (for CDK, MAP kinase, glycogen synthase kinase, and CDK-like), the STE group (homologs of STE11 and STE20), and the CK1 group (for casein kinase-1), and TKL (tyrosine kinase like). Structural data is now available for representatives of each of the well-populated groups, as well as smaller groups, such as WNKs (with no lysine),¹⁸ revealing that the protein kinases have a common architecture.

2.1. Architecture of Protein Kinases

Protein kinases possess a two-lobe architecture that has been reviewed several times (Figure 1a).^{6,7,19,20,21} Briefly, the N-terminal lobe is composed of a five-stranded β -sheet and a single well-conserved helix, labeled helix C based on the structure of PKA.¹⁹ The C-terminal lobe possesses 6 large helices (D, E, F, G, H, and I) and two β -ribbons, β 7– β 8 and β 6– β 9. The β 7– β 8 ribbon is present in both active and inactive protein kinases. Further, an additional β -strand interacts with β 7– β 8 forming a 3-stranded β -sheet in most protein kinases, but not in PKA. The β -strand is labeled β 5D for its placement in the structure between β -strand 5 and helix D (Figure 1a). The β 6– β 9 ribbon is present only in active kinases (Figure 1a);²¹ β 9 is part of the activation segment. Two smaller helices, labeled P+1 and APE (also called helix α EF)²¹ in Figure 1a, are conserved in active protein kinases. The activation segment and the catalytic loop are also in the C-terminal lobe. The catalytic loop refers to a 7-residue segment (Asp166-Asn172 in PKA) that houses the catalytic aspartate (Asp 166) and lysine residue (Lys168). The activation segment refers to the sequence flanked by the conserved motifs DFG (following β 8; subdomain VII in the nomenclature of Hanks and Hunter²²) and APE (subdomain VIII) (also referred to as “activation loop” or Lip). This segment is variable in size and in many kinases possesses one or more phosphorylation sites that tend to be activating.²¹ The primary substrate recognition pocket, the P+1 binding site, is adjacent to, and contiguous in sequence with, the activation segment (Figure 1b). Further, relatively short (~50 residue) N- and C-terminal extensions from the kinase core may pack on the core, and are present for all of the Ser/Thr kinases studied crystallographically, including the smallest, CDK2.²³ Longer N- and C-terminal extensions are known to fold into a variety of separate domains (as reviewed in ref 1). Structural data for Ser/Thr kinases possessing separately folded domains (either a separate subunit or folding unit) is available for twitchin²⁴, p21-activated protein kinase (PAK1),²⁵ CK2 (casein kinase-2),²⁶ G-protein-coupled receptor kinase-2 (GRK2),²⁷ and PKA.²⁸

Protein kinases have grooves on the surface of the kinase core (Figure 1b). The grooves are a consequence of the architecture, and tend to be conserved. For example, in the structure of PKA, a groove is present between helix C and the N-terminal domain β -sheet, which is conserved in AGC kinases. The grooves serve different functions in homologous kinases, as discussed below.

2.2. Available Structural Data

Structural information is available for both active and inactive forms of at least one member of each of the major subgroups of Ser/Thr kinases⁶ (Table 1). Active conformations are closely similar among all groups, such that structural signatures for active kinases have been defined.^{7,23,29} The categorization of “active” versus “inactive” in Table 1 is based upon the position of a conserved threonine, discussed below, as well as other signatures. In the AGC group, PKA,³⁰ PDK1 (phosphoinositide dependent protein kinase),³¹ PKB³² and GRK2³³ have known structures. Most AGC structures are in their active conformations; however, an inactive form of PKB has been determined³⁴. In the CaMK group, the structures of twitchin,^{24,35} titin,³⁶ CaMK-I,³⁷ PHK (phosphorylase kinase)³⁸ are available. Most of these structures are inactive conformations (Table 1), although the structure of PHK has been solved in an active, substrate bound conformation.³⁹ In the CMGC group, the structures of CDK2²³ and many other CDKs (Table 1) in both inactive and active forms have also been determined.^{40,42} The MAP kinases ERK2,^{29,43} p38 α ,^{44,45} JNK3⁴⁶ and others have been solved. Both inactive and active conformations are available for rat ERK2.^{29,43} In addition, glycogen synthase kinase GSK3¹³ and CK2,^{26,47,48} and more^{49,51} of the CMGC group have been studied. In the casein kinase 1 group (CK1), CK1 from *S. pombe*⁵² and rat CK1 δ ,⁵³ both in the active conformations are available. Further, data are at hand for the CMGC group SR protein kinases (SRPKs) Sky1p⁴⁹ and SRPK1 (Table 1). In the STE family, structures are available for inactive p21-activated protein kinase (PAK1)²⁵ and active forms conformation of the MAP3K TAO254 and PAK1.⁵⁵ The data available in the STE group has recently doubled through the efforts of the Structural Genomics Consortium, Oxford (SGC, Table 1). In the tyrosine kinase-like group (TKL), structures are available for the kinase domains of B-RAF (inactive)⁵⁶ and the TGF β receptor.^{57,58} Also, structures are available for small groups, including WNK1 and PknB.^{59,60} Current comprehensive listing of protein kinase Protein Data Bank entries can be found at <http://cellsignaling.lanl.gov/structure/kinase> and <http://www.kinaset.net.org>, and sequence information is available at <http://www.kinase.com/>.

Ser/Thr kinases have been studied structurally in complex with peptides derived from substrates and other interacting proteins (Table 2). Peptides encompassing the site of phosphorylation in substrate, which bind to the active site, have been defined structurally in relatively few kinases. These are PKA^{30,51,62} and PKB³² in AGC group, phosphorylase kinase γ (PHK)³⁹ and Pirn-1¹² in the CaMK group, and CDK2^{63,64} in the CMGC group. The paucity of structural data may be due to poor K_m 's (~ 0.5 mM range) of active-site directed peptides.^{39,65–67} On the other hand, at this point it is usually apparent when a structure is that of an active kinase. For example, the structures of two CK1s, and the STE20s TAO2 and PAK1 (Table 1) have been defined in uncomplexed but active conformations, thus providing some information about their substrate binding modes. Below we discuss interactions in the P+1 specificity pocket.

Rather than binding substrates tightly at the active site, many kinases utilize docking interactions in grooves outside the active site to engage “docking motifs” in substrates and other molecules. Docking interactions have been defined structurally in the CMGC group and in the AGC group (Table 2, Figure 1b). The first to be published was CDK2/cyclin A in

complex with a peptide derived from p27^{Kip},⁴² but several other cyclin A/peptide interactions have been studied.^{63,67} In MAP kinases, part of the CMGC group, a docking groove is present in the C-terminal lobe, and structural data are available for p38 α ⁶⁸ and JNK1,⁶⁹ as well as ERK2,^{70,71} and the *S. cerevisiae* MAP kinase Fus3 in complexes with substrates⁵¹ and other interacting proteins.⁷² Further, SR protein kinases (SRPKs) are CMGC family members that phosphorylate serine arginine rich (SR) protein splicing factors, and a complex of SRPK1 in complex with a substrate derived peptide has been studied⁷³. In the AGC kinases, a pocket is present in the N-terminal lobe (the hydrophobic motif (HM) pocket) that is utilized by phosphoinositide-dependent protein kinase (PDK1) to bind substrates, and by other AGC-group kinases for diverse purposes. Structural data are available for PDK1 lacking HM peptide^{31,74} and for PKB both with³² and without⁷⁵ HM peptide. Some of these structures have been reviewed.^{4,76} In addition, data are available for Aurora kinase^{77–78} and G-protein-coupled receptor kinase GRK2,^{27,79,80} which also utilize the HM pocket for subunit interactions. A docking interaction has also been defined recently for the STE group kinase TAK1, in complex with its activator TAB1.⁸¹

3. Recognition in the P+1 Specificity Pocket

With data available on all of the major groups of Ser/Thr protein kinases, much of the spectrum of active site substrate recognition modes can be defined. This is especially tractable for the P+1 specificity pocket. It is the only pocket constructed to accept a single amino acid from substrate, and is a frequent specificity determinant.^{14,82,83} Further, the P+1 pocket is a regulatory site and is often refolded in inactive forms of protein kinases.²¹ Here we review the three major P+1 pocket recognition modes in Ser/Thr protein kinases. This site is the locus of specificity determination in tyrosine kinases as well^{50,84} and binds the P0 tyrosine.

The P+1 binding pocket of all Ser/Thr protein kinases adopts a similar architecture with respect to the backbone of the polypeptide, as typified by PKA (Figure 2a).^{7,85} In PKA, Leu198–Leu205, residues directly following the activation segment phosphorylation site form the pocket. The salient features are a helical turn (from Thr201 to Leu205) that forms one wall of the pocket, the residues preceding the helix, which form the upper rim of the pocket, and a hydrophobic residue, Leu205 at the bottom. Thr201, a catalytic residue, faces the active site (discussed below). Residues on the outside of the helix, Glu203 and Tyr204, face the interior of the protein. Following this structure is the APE helix (Table 3, Figures 1a, 2b–2e).

3.1 AGC, CAMK and STE Kinases

The P+1 sites of AGC kinase substrates are known to be hydrophobic.⁸³ The structure of PKA⁶¹ revealed hydrophobic residues (Pro202, Leu198, and Leu205) lining the P+1 pocket in the sequence ¹⁹⁸LCGTPEYL²⁰⁵ (Table 3). The substrate is recognized also by Gly200, which adopts a left hand configuration ($\phi=147^\circ$, $\psi=157^\circ$) (Figure 2a) such that the carbonyl of Gly200 points up and can accept a hydrogen bond from the substrate (Figure 2b). Tyr247 at the beginning of helix G also contributes to the pocket. Similar interactions are observed in PKB³². As can be seen in Figure 2b, the P+1 pocket is situated adjacent to active site

residues, such as Asp166 and Lys168; and is contiguous with the activation segment and phosphothreonine, pThr197.⁸⁶

Two other major groups of protein kinases are hydrophobic-directed in the P+1 site, the CaMK group and the STE group. Two structures are available of members of the CaMK group, phosphorylase kinase γ (PHK),^{7,39} and Pim-1.¹² The structure of PHK, in complex with a heptapeptide possessing a phenylalanine at the P+1 site (Figure 2c), reveals similarities to PKA. PHK has the glycine (Gly185), proline (Pro187), and other hydrophobic residues that are hallmarks of hydrophobic-directed kinases including Leu190 at the bottom of the pocket (Table 3). Pim-1 offers a slight variation, with a specificity for alanine at P+1. The structure of Pim-1 kinase in complex with a substrate derived peptide reveals the glycine (Gly203 in Pim-1) accepting a hydrogen bond from substrate, as in PKA. However, the proline is replaced by alanine, and the P+1 pocket is filled with the side-chain of Phe201 in the activation segment, reducing the space for substrate (not shown). CaMK and AGC kinases have been shown to be especially poor enzymes toward substrates that have proline in the P+1 site.⁸⁶

STE group kinases are also directed toward substrates with a hydrophobic residue in the P+1 site. This is apparent from the sequences of known substrates and from screening for kinase activity with peptide libraries.⁸² The STE group is named for several of the proteins that produce sterile phenotypes in yeast,⁸⁷ STE11, STE7 and STE20.^{1,88} STE11 and STE7 are STE kinases involved in three-tiered kinase signaling modules, the MAP kinase cascades (reviewed in refs 89–93). Each MAP kinase cascade activates a specific MAP kinase (which are CMGC kinases, discussed below). STE11s are MAP3Ks (or MEKK (for MAP/ERK kinase kinase), phosphorylating MAP2Ks) and STE7s are MAP2Ks (or MEKs (for MAP/ERK kinase), that phosphorylate MAPKs). STE20 phosphorylates and activates STE11 and is thus referred to as a MAP4K.⁹⁴ Close STE20 homologs such as PAK1 are putative MAP4Ks.^{88,90,95,96} MAP3Ks (including STE11) phosphorylate MAP2Ks on two residues in their activation segments.⁹⁷ The MAP2K MEK2 has the sequence DS*MANS*F,⁹⁷ and both of the phosphorylation sites are followed by a hydrophobic residue. Similarly, the MAP2Ks MEKs 3 and 6, which are phosphorylated, for example, by the MAP3K TAO2,⁹⁸ have the phosphorylation motif DS*VAKT*I. MAP4Ks phosphorylate MAP3Ks on a Ser/Thr followed by a hydrophobic residue (in TAO2, the sequence is PANS*F). Other MAP3Ks have related sequences. Although structures of STE group kinase substrate complexes are not available, the structures of the STE kinases TAO2⁵⁴ and PAK1⁵⁵ have been solved in active conformations. The P+1 pockets of these proteins resemble that of PKA. In TAO2, for example, the pocket is lined by Phe182, Gly184, Pro 186, Met189, and Leu234, all having homologous counterparts in PKA. On the other hand, the MAP2Ks (and STE7s), which are members of the STE group, exhibit dual specificity⁹⁹ toward Ser/Thr and tyrosine,^{100,101} and thus must have unique interactions in the P+1 pocket. The mechanism for this dual specificity has yet to be elucidated.

In addition to the similarities in P+1 site recognition discussed above, AGC, CaMK and STE kinases have been shown recently to have common recognition modes for residues N-terminal to the P0 site of substrates.¹⁰²

3.2. CMGC Kinases

The specificity of CMGC kinases in the P+1 site is either for proline or the P+1 site is not a strong specificity determinant. CDKs and the MAP kinases are proline directed at the P+1 site of substrates.¹⁴ In the CMGC kinases GSK3, CK2, and SR kinases, the P+1 site is not a strong specificity determinant. The structure of CDK2/cyclin A in complex with substrate peptide reveals how the P+1 pocket is arranged to bind proline in CDK2.⁶⁴ The P+1 pocket is formed by the sequence is ¹⁶³VVTWLWYR¹⁶⁹ (Table 3). The backbone of the polypeptide forms a helical turn, as in PKA (Figure 2d). However, the P+1 pocket is filled by the side chain of Arg 171 (Leu205 in PKA), so there is no room for a side chain from substrate. Further, Gly200 of PKA is replaced by Val163. Val163 also adopts a left-hand configuration, and the carbonyl accepts a hydrogen bond from Arg171, creating a flat surface with no potential for hydrogen bonding with substrate. Since the proline in substrate has no hydrogen-bonding potential, this feature probably contributes to the proline specificity of CDK2.^{10,29,103}

MAPKs are CMGC kinases that phosphorylate microtubule associated protein-2 (MAP-2) kinase in response to insulin,¹⁰⁴ and were cloned¹⁰⁵ based on its activity as an S6-kinase, and the regulation of these proteins by MAP kinase has been extensively studied.^{89,90,106} MAP kinases are also proline directed.^{65,107,108} The phospho-tyrosine of active ERK2 is in the P+1 site (Figure 2e).¹⁰⁰ From the structure of active ERK2,²⁹ and by homology with CDK2, it appears that the proline residue of substrate may interact directly with pTyr185, although no structural data is available for a MAP kinase with substrate bound in the active site. pTyr185 binds to Arg192, which extends out from the bottom of the P+1 pocket, and with Arg189, which is on the edge of the pocket (Figure 2e). Phosphotyrosine 185 is required for ERK2 activity and cannot be replaced by other amino acids.¹⁰⁹ This may be partly explained by the remodeling of the activation segment induced by pTyr185.²⁹ The structure of doubly phosphorylated p38γ,⁴⁵ another MAP kinase, is similar. (The active site of ERK2 is reviewed in ref 10.)

Glycogen synthase kinase-3 (GSK3) is another CMGC group member.¹¹⁰ GSK3 has recently become the object of intense study due to its involvement in pattern formation (reviewed in ref 111), neurodegeneration,¹¹² and insulin signaling, and is a drug target for diabetes, Alzheimer's disease and cancer.¹¹³ Structures of GSK3 are available,^{13,17,114–116} and have been reviewed.^{4–10} Its substrate specificity,^{110,115,117} and its pathway involvement¹¹⁷ have also been reviewed. Many substrates of GSK3 require substrate "priming" (prior phosphorylation) at the P+4 site of substrate,¹¹⁵ and the importance of the P+1 site appears to be diminished. The structures of GSK3 were surprising though, because GSK3 is phosphorylated on Tyr216 in the activation segment, and resembles ERK2, which is proline-directed. Quite recent studies show that GSK3 phosphorylates a *bone fide* substrate, LDL-related protein-6, at positions containing proline in the P+1 site, and do not require priming.¹¹⁸ This result is consistent with the similarity of GSK3 and ERK2.

SR protein kinases (SRPKs) are CMGC family members that phosphorylate serine arginine rich (SR) protein splicing factors¹¹⁹ processively¹²⁰. The SRPKs 1 and 2 are specific for sequences in substrates containing arginine in the P+1 position, but can accept proline,^{121,122}

whereas the SR kinase Sky1p^{123,124} is proline directed. The structures of SRPK1⁷³ and Sky1p⁴⁹ have been determined. Although no active site complex is available, the structures are very similar to ERK2, with two arginines in positions homologous to Arg189 and Arg192 of ERK2 (Figure 2e). The phosphotyrosine of ERK2 is replaced by an aspartic acid in SRPK1, which may contribute to the specificity for arginine. The homologous residue in the proline-directed Sky1p is serine. Thus the SR proteins are similar to GSK3, discussed above, and can accept both proline and other residues in the P+1 site. The SR kinases are interesting also because they build a P+1 pocket very similar to other kinases, but do not rely on activation segment phosphorylation.^{21,49}

Casein kinase 2's (CK2s, or CKIIs) are a subgroup of CMGC kinases for which the P+1 site of substrates is not a strong specificity determinant, but sometimes has specificity for negatively charged residues. CK2s have hundreds of putative substrates.¹²⁵ The physiological substrates, and the pathways in which CK2s function are currently being defined.¹²⁶ Studies based on peptide libraries show that the P+1 site of substrate may be proline, aspartic acid, glutamic acid, or serine.^{127,128} Although no structural data is available for CK2 in complex with substrates, based on the uncomplexed structure of CK2 CKII α ^{26,47} it has been proposed¹⁰ that a lysine residue (Lys198 in CKII α), that replaces the Arg191 of ERK2, (Figure 2e) may explain the specificity for acidic residues.

3.3. CK1 Kinases

The CK1s (casein kinase 1) are Ser/Thr protein kinases involved in DNA repair, vesicle trafficking, cell cycle progression and WNT signaling¹²⁹, and common in *C. elegans*.¹³⁰ The P+1 site is not a strong specificity determinant. Instead, as with GSK3, substrate priming at sites C-terminal to P0,^{131,132} as well as an acidic patch N-terminal to the phosphorylation site,¹⁴ dominate interactions. Sequences of CK1s are similar to each other but diverge from other protein kinases both at the beginning and end of the P+1 pocket (Table 3). Although no substrate complex is available for CK1 family members, active conformations of two CK1s have been determined. The structure of CK1 from *S. pombe*⁵² is in an active conformation in the P+1 site (discussed below). The P+1 site looks quite similar to PKA, except that a methionine corresponding to Leu205 of PKA completely fills the pocket, leaving a shallow depression (Figure 2f). In CK1 *S. pombe*⁵² Thr181 in the activation segment, and Tyr230 in helix G occlude the pocket (Figure 2f). In both of these CK1s, the unusual sequence SINTH following the P+1 binding pocket mediates different interactions with helix I.

3.4. The Active Site Residue Thr201 and Remodeling of the P+1 Pocket

Thr201 (PKA numbering) is on the upper rim of the P+1 pocket. It is highly conserved, although replaced by Ser in CK2s. Thr201 forms hydrogen bonding interactions with the catalytic aspartate in Ser/Thr protein kinases (Asp166) and a catalytic lysine (Lys168) (Figures 2b).^{7,10,85,133} Mutation of this residue abolishes catalytic activity toward peptide substrates and autophosphorylation.⁸⁵ Phosphorylation of this residue inhibits the kinase MARK/PAR-1.¹³⁴

The placement of this conserved threonine residue is affected by activation segment phosphorylation. Activation segment phosphorylation induces conformational changes^{7,29,135} that can extend from the DFG at the N-terminus^{7,135,136} through the P+1 specificity pocket at the C-terminus of the loop (the extent of remodeling is indicated in Table 3). In many kinases, the remodeling includes Thr201 (or the homologous residue). Thus the placement of Thr201 is one hallmark of the active conformation.

Several protein kinases are massively remodeled in the P+1 site (Table 3) in inactive versus active structures. The STE20 kinase PAK1, the kinase WNK1, and the CaMK group kinase MNK-1 exhibit the greatest extent of remodeling (Table 3). In the STE20 PAK1, remodeling involves most of the P+1 site helix, extending to Trp430 into the motif ⁴²⁹YWMAPE⁴³⁴.^{25,54} Tyr429–Trp430 are involved in an elaborate conformational switch between inactive and active PAK1.^{25,54,55} This motif is conserved in most STE20 homologs,⁵⁴ and thus similar activation mechanisms may be present in other STE group kinases. A similar degree of remodeling is present in the low activity form of WNK1.⁵⁹ The CaMK group kinase MAP kinase interacting kinase (MNK-1) is remodeled from the DFG motif at the beginning of the activation segment through the beginning of helix F¹³⁷. In several cases, inactive forms involve conformational changes in Thr201 (or the homologous residue). Thus, remodeling in this region affects both substrate binding and catalytic activity. It is interesting that remodeling of the P+1 pocket has been observed in at least one member of each of the major groups of kinases (Table 3).

To summarize the discussion of the P+1 pocket recognition and remodeling, first, it is becoming clear that there are only a few binding modes for the P+1 residue in substrates of Ser/Thr protein kinases. Second, the recognition modes tend to be maintained within each group. The AGC, CaMK, and STE groups recognize hydrophobic residues in the P+1 site. Many members of the CMGC group are proline-directed. Otherwise, the P+1 site is not a strong determinant, and the P+1 pocket has been reduced to a surface depression. Third, it is interesting that the P+1 specificity can be overridden. Examples include CK2, and CK1, each of which recognizes “primed” substrates. Nevertheless, the default P+1 specificity is also used for some substrates. Fourth, structural data on uncomplexed kinases support observed P+1 site preferences, even when structures of complexes are not available. Fifth, the P+1 pocket is remodeled in inactive forms of at least one member of each group of protein kinases. Finally, the fact that the catalytic residue Thr201 is remodeled, along with other residues in the P+1 pocket, implies that inactive forms are deficient in both substrate recognition and catalysis.

4. Docking Interactions

One solution to conferring specificity in the very large protein kinase family is the evolution of new binding sites for substrates and other interaction proteins. Binding sites outside the active site are referred to as docking grooves, and occur on the surface of the kinase domain or in adaptor proteins. These grooves interact with contiguous peptide sequences in substrates referred to as docking motifs or docking sites. Here we will focus on five of these interactions, those of the MAP kinase ERK2, PKA and PKB, CDK2/cyclinA/p107, and SR protein kinases. Mechanisms of specificity determination will be compared. The effect of

docking interactions on substrate affinity, and the data suggestive that allosteric conformational changes contribute to pathway specificity will be discussed.

4.1. Docking Interactions in MAP Kinases

Twelve years ago it was discovered that the MAP kinase c-Jun kinase (JNK) binds its substrates outside the active site, engaging substrate sequences distal from the site of phosphorylation.^{138,139} Since then, a large body of data has accumulated showing that all MAP kinases studied use docking interactions to bind substrates. Further, the MAP kinases engage their activating kinases, phosphatases, and scaffolding proteins using similar docking interactions (reviewed in refs 4,140–147). The “D-motif” docking site, present in MAP kinase interacting proteins, is best studied. D-motif peptide complexes with target MAP kinases have been the object of six recent crystallographic studies (Table 2). The structures span the spectrum of MAP kinase binding partners. Structures of p38 α were determined in complex with substrate and activating enzyme-derived peptides,⁶⁸ JNK1 in complex with a scaffold-derived peptide,⁶⁹ *S. cerevisiae* MAPK Fus3 in complex with substrate,⁵¹ MAP2K3,⁵¹ and scaffold⁷² derived peptides, and ERK2 in complex with MAP2K-derived⁷⁰ and two different phosphatase-derived peptides.^{70,71} Each peptide binds to homologous loci. In this review, we focus on ERK2 in complex with a peptide derived from hematopoietic protein tyrosine phosphatase (HePTP), the structure of which we determined recently, and which revealed the most extensive interactions seen to date. The structural data show that D-motif docking interactions contribute to specificity not only through unique interactions in the docking groove, but through allosteric effects that remodel the activation segment and active site of the MAP kinase.

D-motifs directed toward MAP kinases encompass ~13–16 residues, X $\emptyset$ _H XX(R/K)₂-X₂₋₄- $\emptyset$ _A-X- $\emptyset$ _B, featuring a separation of charged (R/K) and hydrophobic elements ($\emptyset$). The docking groove for D-motifs in MAP kinases was defined by mutational analyses.^{143,148–150} The docking groove was found to be in the C-terminal lobe of the kinase, near the β 7– β 8 reverse turn (Figure 3a), and an acidic patch in L16 (the linker at the C-terminus of the kinase lobe⁴³) labeled the “CD”, for common docking domain.¹⁴³ In the ERK2/pepHePTP complex, the 16-mer peptide from HePTP phosphatase forms an alpha helix over the first six residues and then is extended.⁷⁰ The helix binds in a shallow depression formed where the CD domain in L16 binds atop helix F. The complex reveals the importance of the $\emptyset$ _H: it gives the helix a hydrophobic face. The helix orients the basic residues (R20' and R21') in the peptide toward the CD domain forming an elaborate network of ionic hydrogen bonds. The extended segment of pepHePTP, including the $\emptyset$ _A-X- $\emptyset$ _B motif, is laced perpendicularly over two helices, D and E and under the β 7– β 8 reverse turn. The backbone of the peptide is recognized through hydrogen bonds to Gln117 and His 123 (in the loop between helices D and E of ERK2). The $\emptyset$ _A-X- $\emptyset$ _B motif contacts residues in the two helices $\emptyset$ _A to helix E and $\emptyset$ _B to helix D. There is considerable heterogeneity among the MAP kinases in their interactions with D-motifs, both with the CD domain and the hydrophobic docking groove,^{51,70} which doubtless contributes to specificity among MAP kinases. The binding site that forms the MAP kinase docking groove is present in many protein kinases, and is often utilized to bind the kinase C-terminal tail.^{4,54}

4.2. HM Motifs in AGC Kinases and AGC Kinase Substrates

In the AGC group, a group-specific pocket called the HM pocket for (hydrophobic motif binding pocket) in the N-terminal lobe is formed by helix B, which prevents helix C from packing tightly on the core β -sheet (Figures 1b and 3b). This pocket serves different purposes in different AGC kinases.^{3,4} In PKA, the C-terminal sequence FTEF-COOH binds in the pocket (Figure 3b). In other AGC kinases,^{3,4} such as PKB, the kinase C-terminal tail possesses a hydrophobic motif (HM) FXXF-S/T-F/Y, and must be phosphorylated (or replaced with a phosphorylation site mimetic) to bind to the pocket.¹⁵¹ The AGC kinase phosphoinositide-dependent protein kinase (PDK1) lacks the hydrophobic motif altogether. Instead, the HM is present in PDK1 substrates. The binding of substrates both activates^{152,153} and stabilizes^{74,154} PDK1. This mechanism is potentially very powerful at conferring specificity, since PDK1 is not active in the absence of its substrate.

Structural data illuminating how HM-peptides may interact with AGC kinases came first from the structure of PKA (Figure 3b).¹⁵⁵ The four residues Phe347–Phe350 form a hairpin turn that brings the two phenylalanine residues in close proximity. Phe347 packs against a valine in helix B, and Phe350 contacts the aliphatic part of the side-chains of two lysine residues, one in helix C (Lys92) and one extending β 4 (Lys111). The terminal carboxylate of PKA is also bound by the same two lysine residues. The backbone of the hairpin turn is contacted by Lys111. Thus, there is an exquisite interaction, requiring two phenylalanine residues separated by two intervening residues, accompanied by a negative charge adjacent to the second phenylalanine. Structural data on PKB HM interactions were obtained by mutating the C-terminal phosphorylation site to aspartic acid (S474D) and by making a chimera with another HM.⁷⁵ The interactions are similar but more extensive (not shown). Other AGC kinase-HM interactions have been studied structurally. The G-protein coupled receptor kinase GRK2 uses this site intramolecularly to bind the RGS-homology domain,^{27,79,80} whereas Aurora kinase uses the same groove binds interacting proteins.^{77,78} Finally, the TKL family enzyme TGF β receptor (transforming growth factor receptor-beta) also uses this groove to bind the interacting protein FKBP12.⁵⁸

4.3. CDK2/Cyclin A Recruitment Peptide Interactions

CDKs bind substrates and inhibitors through cyclin mediated interactions (reviewed in refs 155,156). The cyclin inhibitor p21 binds cyclin A via a recruitment peptide sequence, ACRRFLFGP, and similar sequences are present in related inhibitors.¹⁵⁸ Substrates of CDK2 such as the tumor suppressor Rb and p107, and the transcription factors E2F also possess related recruitment sequences.¹⁵⁹ Only a short motif, RXL Φ , where the hydrophobic amino acid Φ is either adjacent to RXL, or displaced by one residue, is conserved (Table 4). Several complexes of CDK2/cyclin A with inhibitor or substrate derived recruitment peptides have been studied structurally (Table 2), and also well-illustrated.^{41,63} We focus on the structure of CDK2/cyclin A/p 107 peptide (Figure 3c) as an example.⁶³ This has two domains, the first of which binds recruitment peptides. The recruitment peptide binding domain is comprised of five helices, the first three of which resemble the first three helices of an antiparallel four-helix bundle.¹⁶⁰

Two short helices pack orthogonally on one of the major helices, helix 3, such that the loop connecting them falls near the intersection of helices 1 and 3. The peptide binding groove is a shallow V-shaped hydrophobic crevice between helices 1 and 3 and the helix 4–helix 5 loop. The recruitment peptide adopts a primarily extended conformation. The conserved leucine in the motif RXL Φ is defined as P₀ by Lowe *et al.*⁶³ The leucine, as well as the Φ residue in the P₁ position, binds in the crevice between helices 1 and 3. The conserved arginine (P₋₂) lies across the top of helix 1, and forms an ion pair with Glu220 in helix 1. Interactions with the peptide backbone are made by a glutamine in helix 3 (Gln254), and the backbone of a residue in the loop between helix 4 the helix 5 (Ile281). This simple binding groove, then, confers recognition of a positive charge separated by one residue from two hydrophobic amino acids.

The recruitment site in cyclin A is about 35 Å away from the catalytic site, and the mechanism for enhancing substrate phosphorylation was originally proposed to raise the local concentration of the protein substrate.¹⁶¹ A recent elegant study⁶⁷ utilizing a ATP-mimetic bisubstrate inhibitor¹⁶² has allowed a 30 residue peptide spanning from the active site to the recruitment site to be visualized. Indeed, several residues between the recruitment site and active site are disordered, validating the concept that recruitment interactions increase the local concentration of substrate. The authors also show that improvement in catalytic efficiency is primarily a K_m effect, which goes down 18-fold for substrate with RXL containing substrates (see also 163). No conformational changes are induced in CDK2/Cyclin A by the interaction with recruitment peptide⁶³ or bisubstrate peptide⁶⁷.

4.4. SRPK Docking Interactions

SRPKs phosphorylate subsets of available serine phosphorylation sites within the target “RS”-domains of substrates, and the exact position of phosphorylation is thought to direct the outcome of alternative splicing mediated by the SR proteins.^{122,73} Ngo *et al.*⁷³ have determined the structure of a truncation of SRPK 1 in the presence of substrate derived peptide (RERSPTR), and found that the peptide binds in a docking groove, rather than at the active site. They further demonstrate the presence of this docking site in one of its substrates, the splicing factor ASF. The docking interaction appears to sequester phosphorylation sites as well as limit the phosphorylation at other sites⁷³. The docking groove is formed where an insert in the connection between helices F and G unique to the SR kinases causes helix G and a two turn helix in the MAP kinase insertion (labeled $\alpha 3_{L14}$)⁴³ (Figures 1b, and 3e) to be farther separated than in MAP kinases. Arg1 of the peptide (Figure 3e) is recognized by two Asp564 and Glu571 in helix G, residues separated by two turns of helix. Arg3 contacts two carbonyls in the helix F/helix G connection, and Arg7 contacts the backbone of Tyr181 at the terminus of helix D and Thr546 in the helix F/G connection. The peptide backbone makes only a single contact Lys615 at the end of helix G. The only hydrophobic interactions are with the aliphatic portion of the Arg3, representing a major departure from the themes observed in other kinases. Peptide interactions do not induce any conformational changes in SRPK1 (see 1 WAK.pdb). The recent structure of STE group kinase TAK1, in complex with its activator TAB1 reveals a similar locus of interactions to ASF/SF2, but the binding site is more extensive.⁸¹

4.5. Similarities and Differences in Docking Interactions

The docking interactions described above have some interesting parallels. First, each peptide primarily adopts an extended conformation, but may have some internal hydrogen bonding. This hydrogen bonding can be significant, such as the small helix as in HePTP bound to ERK2, to just a few hydrogen bonds, as in p107 bound to CDK2/cyclin A. Second, the backbone of the peptide is recognized in each case. In ERK2 and other MAP kinases, a glutamine, or a glutamine and histidine make hydrogen bonds with the peptide backbone. In cyclin/p107 a histidine residue as well as the backbone of the helix 4 – helix 5 loop contact the peptide. In PKA, a lysine residue (Lys111) contacts the peptide backbone. Similarly, in SRPK1, a lysine contacts the peptide backbone. A third similarity, among ERK2, PKA, and CDK2/cyclin A, is the presence of binding sites for two or more hydrophobic residues. Finally, the binding grooves invariably involve two or more helices, as well as a loop or additional secondary structure.

There are also interesting differences which surely confer specificity among these groups of kinases. Among the groups that bind hydrophobic residues, the docking grooves are organized to bind residues separated by a different spacing: Cyclins bind adjacent hydrophobic residues or residues separated by one amino acid in a depression formed by two parallel helices in contact that form the docking groove. MAP kinases recognize hydrophobic residues separated by one amino acid, through well-separated pockets, on two different helices. A glutamine residue contacts the peptide backbone between the two hydrophobic residues. AGC kinases bind HM peptides that possess hydrophobes separated by two amino acids. The binding pockets are deep and close together, and an intricate network of hydrogen bonds recognizes a hairpin turn in the HM peptide. A second obvious difference between the binding grooves in MAP kinases, AGC kinases and cyclins is the relative orientation of the hydrophobic versus charged and hydrogen bonding functionalities, which is necessary to bind the distinctive docking motifs (Table 4).

As more kinase-substrate complexes are studied, it is becoming clear that larger surfaces of substrates can be involved in recognition. For example, the complex of PKR, a CMGC kinase, with its native substrate eukaryotic translation initiation factor 2 α (eIF2 α)⁵⁰ involves helix G of the kinase and an entire surface of the eIF2 α β -barrel (not shown). Interestingly, the interaction of PKR with eIF2 α works allosterically on the eIF2 α inducing disorder in the loop containing the phosphorylation site. This may be important for active site recognition.

4.6. Allosteric Properties of Docking Interactions

The recent structures of MAP kinase docking peptide complexes and the AGC kinase PKB have revealed allosteric conformational changes that serve functions other than enhancing substrate recognition. In PKB, the allostery serves to activate the kinase. In MAP kinases, the allostery does effect active site binding of substrates, but also influences binding of processing kinases and phosphatases that act on the activation loop. These conformational changes appear to be potent methods for enhancing pathway specificity.

4.6.1 Allostery in MAP Kinase Docking Interactions—In both ERK2⁷⁰ and p38 α ,⁶⁸ D-motif docking peptides induce conformational changes in the activation segment (Figure 4a). In ERK2, a new conformation of the activation segment is adopted (Figure 4a). In p38 α , the activation segment becomes disordered and more susceptible to proteolysis (unpublished results). Conformational changes in ERK2 occur in solution also.¹⁶⁴ What is the function of these conformational changes? Structural studies are available exclusively for unphosphorylated enzymes, and thus the most physiologically relevant structures involve MAP2K-derived peptides. Consider the action of MEKs, which phosphorylate MAP kinases. The phosphorylation sites of MAP kinases are sequestered or well-tethered in the low activity conformers. In unphosphorylated ERK2,⁴³ Tyr 185, the residue phosphorylated first by MEK1/2,¹⁰¹ is buried under the backbone of the activation segment. In p38 α ,^{44,45} although the Tyr182 phosphorylation site is on the surface, it forms numerous intramolecular contacts. These contacts probably prevent other kinases from accessing MAP kinase phosphorylation sites. Thus, this allosteric mechanism may contribute to pathway specificity. A prediction is that docking peptides added in trans to docking-motif truncated kinases (or phosphatases) might facilitate activity, but this has not been reported so far. It may be such studies must be conducted at a very high protein concentrations to account for the local concentration effect of the docking interaction, as observed for CDK2/cyclin A⁶⁷.

The docking study in p38 α showed that substrate derived peptides also induce conformational changes. But function of the conformational change induced by substrate is presumably different. The study of peptide-bound ERK2 provides the best insight, since structural data are available for both inactive and active ERK2. The peptide induced structure is closer to the active form than the inactive form (rmsd 1.8 Å versus 2.4 Å). Thus, it may be that substrate peptides are complimentary to a structure closer to the active form.

The conformational changes induced by docking motif peptides are shown for ERK2 in Figure 4a. The changes occur in the activation segment, and along L16, a linker that contacts both the peptide HePTP, and the activation segment. In p38 α , peptides also induce changes, but the changes are different in detail. In p38 α , the largest change is in the activation segment, but near the peptide binding site the changes are in helix D, and the loop between helix D and helix E (not shown). The linkage between peptide binding and activation segment disorder is unclear, but may involve a relaxation process within the C-terminal lobe of p38 α . Apparently, functionally similar conformational changes are induced by different mechanisms. This difference in allosteric mechanism may contribute further to specificity determination among MAP kinases⁷⁰.

4.6.2. Allosteric Properties HM Motif Interactions in AGC Kinases—As discussed above, AGC kinases use the HM-pocket for different purposes in different kinases: part of the active structure as in PKA, as a binding site for a regulatory segment of the same protein as in PKB or GRK2, or other subunit as in Aurora kinase, or as a substrate binding site as in PDK1. PDK1 is the most intriguing, because it has been shown that the substrate HM both binds and activates PDK1,^{74,152–154} The mechanism for how this might be accomplished comes from the structure of a truncated form of PKB,⁷⁵ lacking the HM (as well as a PH domain at the N-terminus of the kinase) (Figure 4b). This structure reveals massive disorder in helices B and C. Thus, apparently the HM is required to build the active structure of the

PKB. The structure of PDK1 has also been solved in the absence of an HM.^{74,151} No similar disorder was observed, but a lattice contact may have stabilized the HM-pocket.¹⁵¹ Biochemical data (reviewed in ref 4) shows that HM interactions are required for PDK1 to have any activity. Thus, there very probably is an allosteric mechanism activating PDK1 through docking interactions, if not as dramatic as those observed in PKB. The allosteric activation in AGC kinases is very reminiscent of the allosterically induced activation loop changes in MAPKs.

No similar peptide-induced conformational changes have been observed in the CDK2/cyclin A/peptide complexes.^{42,67} On the other hand, docking interaction greatly improves the K_m , as discussed above. Activation segment phosphorylated CDK2 (on Thr160), in the absence of a cyclin, adopts an inactive structure,⁴⁰ and cyclin binding appears to be required to form the active enzyme.⁴¹

4.6.4. Conformational Change Energy—Conformational changes require energy. The conformational change energies (CCE)¹⁶⁵ cannot be measured for these docking interactions. However, CCE's have been measured for several proteins, including hemoglobin, aspartate transcarbamylase, phosphofructokinase¹⁶⁶ and serpins.¹⁶⁷ The observed CCEs range from 3 to 6 kcal (or 3 to 6 orders of magnitude of affinity), with 11 kcal as an upper limit (serpins). Affinities of docking peptides have been measured for the MAP kinase ERK2,¹⁵⁰ and for the AGC kinase PDK1^{152,168}. The affinities were found to be in the micromolar range for both. If similar CCE's apply to MAP kinase and AGC kinase docking interactions, the intrinsic binding energy¹⁶⁹ should be better by at least 3 kcal, or 3 orders of magnitude in affinity. This effect could reduce a nanomolar intrinsic affinity into the observed micromolar range. Thus, it seems probable that allostery may serve to gain high specificity at modest affinities. We think that allostery will prove to be very prevalent in signal-transducing protein-protein interactions for this reason, perhaps as important as compartmentalization¹⁷⁰ and scaffolding¹⁷¹ in specificity determination. A further prediction can be drawn that the docking groove should bind yet-to-be-identified compounds or peptides more tightly than the native substrates, and thus could be a target for drug discovery.

5. Conclusions

With structural data now available on active and inactive forms of each of the major groups of Ser/Thr kinases defined by Hunter and colleagues, several conclusions can now be drawn. First, the P+1 specificity pocket distinguishes the kinase groups from one another. The AGC, CaMK, and Ste groups are hydrophobic directed for P+1 sites, the CMGC group is proline directed (or P +1 is not a strong determinant) and in the CK1 group, the P+1 site is not a strong determinant. The P+1 pocket is also important because it houses a catalytic threonine, Thr201 of PKA. The P+1 pocket and the threonine are remodeled in inactive forms of at least one member of every group of protein kinases. Second, biochemical and structural data have revealed that at least two groups of protein kinases utilize docking in grooves outside the active site to bind substrates and other molecules. Docking strategies are group specific. Third, docking interactions often involve allosteric conformational changes that affect the active site or activation segment. Allostery appears to be a powerful

mechanism to confer pathway specificity by preventing reactions between inappropriate partners. In MAP kinases, one function may be to make the MAP kinase phosphorylation sites available for processing, while inappropriate kinases and phosphatases cannot access these sites. The docking interactions also promote the active structure. In PKB, the HM interaction is used to make the PKB activity dependent on phosphorylation, while in PDK1, the substrate provides the HM peptide. Further, conformational changes absorb intrinsic binding energy, reducing the affinity of substrates, but perhaps not affecting the substrate specificity. For these reasons, allosteric effects may prove to be prevalent in signal-transducing machinery, as mechanisms for conferring specificity among similar proteins. We look forward to further biochemical studies to better understand how kinases are regulated, and to the elucidation of larger protein-protein interactions that serve to define the specificity of protein kinases in the cellular context.

Acknowledgments

We apologize for sins of omission in this review and thank Louise Johnson, Natalie Ahn, Bostjan Kobe, and Zhulun Wang for reading and suggestions. This research was supported by National Institutes of Health grant (DK46993) and from Welch Foundation (I1128).

Abbreviations

AGC	cAMP-dependent protein kinase/protein kinase G/protein kinase C extended family
ASF/SF2	SR human splicing factor
CaMK	Calcium-calmodulin dependent kinase
CCE	Coformational change energies
CDKs	cyclin dependent kinases
CK1	Casein kinase-1
CK2	casein kinase-2
CMGC	CDK, MAP kinase, glycogen synthase kinase, and CDK-like
ERK	Extracellular responsive kinase
GRK2	G-protein-coupled receptor kinase-2
GSK	Glycogen synthase kinase
HePTP	Hematopoietic protein tyrosine phosphatase
HM	Hydrophobic motif
JNK	Jun-N-terminal kinase
MAPKs	Mitogen activated protein kinases
MAP2K	Mitogen activated protein kinase kinase
MAP3K	Mitogen activated protein kinase kinase kinase
MARK	Microtubule-affinity regulating kinase

MNK-1	MAP kinase interacting kinase
Np13p	SR-like RNA binding protein
PAK1	p21-activated protein kinase
PDK1	Phosphoinositide dependent protein kinase
PepHePTP	Peptide from hematopoietic protein tyrosine phosphatase
PHK	Phosphorylase kinase
Pim-1	Phosphatidylinositol mannoside-1
PKA	Protein kinase A
PKB	Protein kinase B
PKC	Protein kinase C
SRPK1	Serine/Arginine rich protein kinases
STE	homologs of STE11 and STE20
TAB1	TAK1 binding protein 1
TAK1	Transforming growth factor-beta activated kinase 1
TAO2	Thousand and one kinase2
TGFβ-receptor	transforming growth factor receptor-beta
TKL	Tyrosine kinase like
WNKs	With no lysine

References

1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. Science. 2002; 298:1912. [PubMed: 12471243]
2. Kostich M, English J, Madison V, Gheys F, Wang L, Qiu P, Greene J, Laz TM. Genome Biol. 2002; 3 Research43.1.
3. Biondi RM. Trends Biochem. Sci. 2004; 29:136. [PubMed: 15003271]
4. Biondi RM, Nebreda AR. Biochem. J. 2003; 372:1. [PubMed: 12600273]
5. Zhu G, Liu Y, Shaw S. Cell Cycle. 2005; 4:52. [PubMed: 15655379]
6. Taylor SS, Kim C, Vigil D, Haste NM, Yang J, Wu J, Anand GS. Biochim. Biophys. Acta. 2005; 1754:25. [PubMed: 16214430]
7. Johnson LN, Lowe ED, Noble ME, Owen DJ. FEBS Lett. 1998; 430:1. [PubMed: 9678585]
8. Kobe B, Kemp BE. Nature. 1999; 402:373. [PubMed: 10586874]
9. Kobe B, Kampmann T, Forwood JK, Listwan P, Brinkworth RI. Biochim. Biophys. Acta. 2005; 1754:200. [PubMed: 16172032]
10. Kannan N, Neuwald AF. Protein Sci. 2004; 13:2059. [PubMed: 15273306]
11. Hubbard SR. Prog. Biophys. Mol Biol. 1999; 71:343. [PubMed: 10354703]
12. Bullock AN, Debreczeni J, Amos AL, Knapp S, Turk BE. J. Biol. Chem. 2005; 280:41675. [PubMed: 16227208]
13. Dajani R, Fraser E, Roe SM, Young N, Good V, Dale TC, Pearl LH. Cell. 2001; 105:721. [PubMed: 11440715]

14. Songyang Z, Lu KP, Kwon YT, Tsai L-H, Filhol O, Cochet C, Brickey DA, Soderling TR, Bartleson C, Graves DJ, DeMaggio AJ, Hoekstra MF, Blenis J, Hunter T, Cantley LC. *Mol. Cell. Biol.* 1996; 16:6486. [PubMed: 8887677]
15. Brinkworth RI, Breinl RA, Kobe BP. *Natl. Acad. Sci. U S A.* 2003; 100:74.
16. Pinna LA, Ruzzene M. *Biochim. Biophys. Acta.* 1996; 1314:191. [PubMed: 8982275]
17. Bax B, Carter PS, Lewis C, Guy AR, Bridges A, Tanner R, Pettman G, Mannix C, Culbert AA, Brown MJ, Smith DG, Reith AD. *Structure (Camb).* 2001; 9:1143. [PubMed: 11738041]
18. Xu B, English JM, Wilsbacher JL, Stippec S, Goldsmith EJ, Cobb MH. *J. Biol Chem.* 2000; 275:16795. [PubMed: 10828064]
19. Knighton DR, Zheng J, Ten Eyck LF, Ashford VA, Xuong N-H, Taylor SS, Sowadski JM. *Science.* 1991; 253:407. [PubMed: 1862342]
20. Taylor SS, Knighton DR, Zheng J, Sowadski JM, Gibbs CS, Zoller MJ. *Trends Biochem. Sci.* 1993; 18:84. [PubMed: 8480367]
21. Nolen B, Taylor S, Ghosh G. *Mol. Cell.* 2004; 15:661. [PubMed: 15350212]
22. Hanks SK, Hunter T. *FASEB J.* 1995; 9:576. [PubMed: 7768349]
23. De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim S-H. *Nature.* 1993; 363:595. [PubMed: 8510751]
24. Kobe B, Heierhorst J, Feil SC, Parker MW, Benian GM, Weiss KR, Kemp BE. *Embo J.* 1996; 15:6810. [PubMed: 9003756]
25. Lei M, Lu W, Meng W, Parrini MC, Eck MJ, Mayer BJ, Harrison SC. *Cell.* 2000; 702:387. [PubMed: 10975528]
26. Niefind K, Guerra B, Ermakowa I, Issinger OG. *EMBO J.* 2001; 20:5320. [PubMed: 11574463]
27. Lodowski DT, Pitcher JA, Capel WD, Lefkowitz RJ, Tesmer JJ. *Science.* 2003; 300:1256. [PubMed: 12764189]
28. Kim C, Xuong NH, Taylor SS. *Science.* 2005; 307:690. [PubMed: 15692043]
29. Canagarajah BJ, Khokhlatchev A, Cobb MH, Goldsmith EJ. *Cell.* 1997; 90:859. [PubMed: 9298898]
30. Zheng J, Knighton DR, Ten Eyck LF, Karlsson R, Xuong N-H, Taylor SS, Sowadski JM. *Biochemistry.* 1993; 32:2154. [PubMed: 8443157]
31. Biondi RM, Komander D, Thomas CC, Lizcano JM, Deak M, Alessi DR, van Aalten DM. *EMBO J.* 2002; 21:4219. [PubMed: 12169624]
32. Yang J, Cron P, Good VM, Thompson V, Hemmings BA, Barford D. *Nat. Struct. Biol.* 2002; 9:940. [PubMed: 12434148]
33. Lodowski DT, Barnhill JF, Pyskadlo RM, Ghirlando R, Steme-Marr R, Tesmer JJ. *Biochemistry.* 2005; 44:6958. [PubMed: 15865441]
34. Huang X, Begley M, Morgenstern KA, Gu Y, Rose P, Zhao H, Zhu X. *Structure.* 2003; 11:21. [PubMed: 12517337]
35. Hu S-H, Parker MW, Lei JY, Wilce MCJ, Benian GM, Kemp BE. *Nature.* 1994; 369:581. [PubMed: 8202162]
36. Mayans O, van der Ven PF, Wilm M, Mues A, Young P, Furst DO, Wilmanns M, Gautel M. *Nature.* 1998; 395:863. [PubMed: 9804419]
37. Goldberg J, Nairn AC, Kuriyan J. *Cell.* 1996; 84:875. [PubMed: 8601311]
38. Owen DJ, Noble MEM, Garman EF, Papagerorgiou AC, Johnson LN. *Structure.* 1995; 3:467. [PubMed: 7663944]
39. Lowe ED, Noble MEM, Skamnaki VT, Oikonomakos NG, Owen DJ, Johnson LN. *EMBO J.* 1997; 16:6646. [PubMed: 9362479]
40. Brown NR, Noble ME, Lawrie AM, Morris MC, Tunnah P, Divita G, Johnson LN, Endicott JA. *J. Biol. Chem.* 1999; 274:8746. [PubMed: 10085115]
41. Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP. *Nature.* 1996; 382:325. [PubMed: 8684460]
42. Russo AA, Jeffrey PD, Pavletich NP. *Nat. Struct. Biol.* 1996; 3:696. [PubMed: 8756328]

43. Zhang F, Strand A, Robbins D, Cobb MH, Goldsmith EJ. *Nature*. 1994; 367:704. [PubMed: 8107865]
44. Wang Z, Harkins PC, Ulevitch RJ, Han J, Cobb MH, Goldsmith EJ. *P. Natl. Acad. Sci. USA*. 1997; 94:2327.
45. Bellon S, Fitzgibbon MJ, Fox T, Hsiao H-M, Wilson KP. *Structure*. 1999; 7:1057. [PubMed: 10508788]
46. Xie X, Gu Y, Fox T, Coll JT, Fleming MA, Markland W, Caron PR, Wilson KP, Su MS. *Structure*. 1998; 6:983. [PubMed: 9739089]
47. Niefind K, Putter M, Guerra B, Issinger OG, Schomburg D. *Nat. Struct. Biol*. 1999; 6:1100. [PubMed: 10581548]
48. Niefind K, Issinger OG. *Mol. Cell. Biochem*. 2005; 274:3. [PubMed: 16335523]
49. Nolen B, Yun CY, Wong CF, McCammon JA, Fu XD, Ghosh G. *Nat. Struct. Biol*. 2001; 5:176. [PubMed: 11175909]
50. Dar AC, Dever TE, Sicheri F. *Cell*. 2005; 122:887. [PubMed: 16179258]
51. Remenyi A, Good MC, Bhattacharyya RP, Lim WA. *Mol. Cell*. 2005; 20:951. [PubMed: 16364919]
52. Xu R-M, Carmel G, Sweet RM, Kuret J, Cheng X. *EMBO J*. 1995; 14:1015. [PubMed: 7889932]
53. Longenecker KL, Roach PJ, Hurley TD. *J. Mol. Biol*. 1996; 257:618. [PubMed: 8648628]
54. Zhou T, Raman M, Gao Y, Earnest S, Chen Z, Machius M, Cobb MH, Goldsmith EJ. *Structure*. 2004; 12:1891. [PubMed: 15458637]
55. Lei M, Robinson MA, Harrison SC. *Structure*. 2005; 513:769. [PubMed: 15893667]
56. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R. *Cell*. 2004; 116:855. [PubMed: 15035987]
57. Huse M, Chen YG, Massague J, Kuriyan J. *Cell*. 1999; 96:425. [PubMed: 10025408]
58. Huse M, Muir TW, Xu L, Chen YG, Kuriyan J, Massague J. *Mol Cell*. 2001; 8:671. [PubMed: 11583628]
59. Min X, Lee BH, Cobb MH, Goldsmith EJ. *Structure*. 2004; 12:1303. [PubMed: 15242606]
60. Young TA, Delagoutte B, Endrizzi JA, Falick AM, Alber T. *Nat. Struct. Biol*. 2003; 10:168. [PubMed: 12548283]
61. Knighton DR, Zheng J, Ten Eyck LF, Xuong N-H, Taylor SS, Sowadski JM. *Science*. 1991; 253:414. [PubMed: 1862343]
62. Bossemeyer D, Engh RA, Kinzel V, Ponstingl H, Huber R. *EMBO J*. 1993; 12:849. [PubMed: 8384554]
63. Lowe ED, Tews I, Cheng KY, Brown NR, Gul S, Noble ME, Gamblin SJ, Johnson LN. *Biochemistry*. 2002; 41:15625. [PubMed: 12501191]
64. Brown NR, Noble ME, Endicott JA, Johnson LN. *Nat. Cell Biol*. 1999; 7:438. [PubMed: 10559988]
65. Haycock JW. *J Neurol. sci. Methods*. 2002; 116:29.
66. Cox S, Taylor SS. *Biochemistry*. 1995; 34:16203. [PubMed: 8519778]
67. Cheng KY, Noble ME, Skamnaki V, Brown NR, Lowe ED, Kontogiannis L, Shen K, Cole PA, Siligardi G, Johnson LN. *J. Biol. Chem*. 2006
68. Chang CI, Xu BE, Akella R, Cobb MH, Goldsmith EJ. *Mol. Cell*. 2002; 9:1241. [PubMed: 12086621]
69. Heo YS, Kim SK, Seo CI, Kim YK, Sung BJ, Lee HS, Lee JI, Park SY, Kim JH, Hwang KY, Hyun YL, Jeon YH, Ro S, Cho JM, Lee TG, Yang CH. *EMBO J*. 2004; 23:2185. [PubMed: 15141161]
70. Zhou T, Sun L, Humphreys J, Goldsmith EJ. *Structure*. 2006; 14:1011. [PubMed: 16765894]
71. Liu S, Sun JP, Zhou B, Zhang ZY. *P. Natl Acad Sci. U S A*. 2006; 103:5326.
72. Bhattacharyya RP, Remenyi A, Good MC, Bashor CJ, Falick AM, Lim WA. *Science*. 2006; 311:822. [PubMed: 16424299]
73. Ngo JC, Chakrabarti S, Ding JH, Velazquez-Dones A, Nolen B, Aubol BE, Adams JA, Fu XD, Ghosh G. *Mol. Cell*. 2005; 20:11.

74. Komander D, Kular G, Deak M, Alessi DR, van Aalten DM. *J. Biol. Chem.* 2005; 280:18797. [PubMed: 15741170]
75. Yang J, Cron P, Thompson V, Good VM, Hess D, Hemmings BA, Barford D. *Mol. Cell.* 2002; 9:1227. [PubMed: 12086620]
76. Goldsmith EJ, Chang CI. *Structure.* 2002; 10:888. [PubMed: 12121643]
77. Bayliss R, Sardon T, Vernos I, Conti E. *Mol. Cell.* 2003; 12:851. [PubMed: 14580337]
78. Sessa F, Mapelli M, Ciferri C, Tarricone C, Areces LB, Schneider TR, Stukenberg PT, Musacchio A. *Mol. Cell.* 2005; 18:379. [PubMed: 15866179]
79. Lodowski DT, Tesmer VM, Benovic JL, Tesmer JJ. *J. Biol. Chem.* 2006; 257:16785. [PubMed: 16613860]
80. Tesmer VM, Kawano T, Shankaranarayanan A, Kozasa T, Tesmer JJ. *Science.* 2005; 310:1686. [PubMed: 16339447]
81. Brown K, Vial SC, Dedi N, Long JM, Dunster NJ, Cheetham GM. *J. Mol. Biol.* 2005; 354:1013. [PubMed: 16289117]
82. Songyang Z, Blechner S, Hoagland N, Hoekstra MF, Piwnicka-Worms H, Cantley LC. *Curr. Biol.* 1994; 4:973. [PubMed: 7874496]
83. Denis CL, Kemp BE, Zoller MJ. *J. Biol. Chem.* 1991; 266:17932. [PubMed: 1917932]
84. Hubbard SR. *EMBO J.* 1997; 16:5572. [PubMed: 9312016]
85. Moore MJ, Kanter JR, Jones KC, Taylor SS. *J Biol. Chem.* 2002; 277:47878. [PubMed: 12372837]
86. Zhu G, Fujii K, Belkina N, Liu Y, James M, Herrero J, Shaw S. *J Biol Chem.* 2005; 280:10743. [PubMed: 15647260]
87. Herskowitz I. *Cell.* 1995; 80:187. [PubMed: 7834739]
88. Dan I, Watanabe NM, Kusumi A. *Trends Cell. Biol.* 2001; 11:220. [PubMed: 11316611]
89. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B, Wright A, Vanderbilt C, Cobb MH. *Chem. Rev.* 2001; 101:2449. [PubMed: 11749383]
90. Widmann C, Gibson S, Jarpe MB, Johnson GL. *Physiol. Rev.* 1999; 79:143. [PubMed: 9922370]
91. Ahn NG. *Mol. Cell. Biochem.* 1993; 127–128:201.
92. Cobb MH, Xu S, Hepler JE, Hutchison M, Frost J, Robbins DJ. *Cell. Mol. Biol. Res.* 1994; 40:253. [PubMed: 7874203]
93. Nishida E, Gotoh Y. *Trends Biochem. Sci.* 1993; 18:128. [PubMed: 8388132]
94. Drogen F, O'Rourke SM, Stucke VM, Jaquenoud M, Neiman AM, Peter M. *Curr. Biol.* 2000; 10:630. [PubMed: 10837245]
95. Chen W, Yazicioglu M, Cobb MH. *J Biol. Chem.* 2004; 279:11129. [PubMed: 14707132]
96. Kyriakis JM. *J Biol. Chem.* 1999; 274:5259. [PubMed: 10026130]
97. Mansour SJ, Resing KA, Candi JM, Hermann AS, Gloor JW, Herskind KR, Wartmann M, Davis RJ, Ahn NG. *J. Biochem.* 1994; 116:304. [PubMed: 7822248]
98. Chen Z, Raman M, Chen L, Lee SF, Gilman AG, Cobb MH. *J. Biol. Chem.* 2003; 278:22278. [PubMed: 12665513]
99. Ben-David Y, Letwin K, Tannock L, Bernstein A, Pawson T. *EMBO J.* 1991; 70:317. [PubMed: 1825055]
100. Ahn NG, Seger R, Bratlien RL, Diltz CD, Tonks NK, Krebs EG. *J. Biol. Chem.* 1991; 266:4220. [PubMed: 1705548]
101. Haystead TA, Dent P, Wu J, Haystead CMM, Sturgill TW. *FEBS Lett.* 1992; 306:17. [PubMed: 1628739]
102. Zhu G, Fujii K, Liu Y, Codrea V, Herrero J, Shaw S. *J Biol Chem.* 2005; 280:36372. [PubMed: 16131491]
103. Khokhlatchev AV, Canagarajah B, Atkinson M, Goldsmith E, Cobb MH. *Cell.* 1997
104. Ray LB, Sturgill TW. *P. Natl. Acad. Sci. USA.* 1987; 84:1502.
105. Boulton TG, Yancopoulos GD, Gregory JS, Slaughter C, Moomaw C, Hsu J, Cobb MH. *Science.* 1990; 249:64. [PubMed: 2164259]
106. Lewis TS, Shapiro PS, Ahn NG. *Adv. Cancer Res.* 1998; 74:49. [PubMed: 9561267]

107. Clark-Lewis I, Sanghera JS, Pelech SL. *J. Biol. Chem.* 1991; 266:15180. [PubMed: 1907971]
108. Haycock JW, Ahn NG, Cobb MH, Krebs EG. *Proc. Natl Acad. Sci. USA.* 1992; 89:2365. [PubMed: 1347949]
109. Zhang J, Zhang F, Ebert D, Cobb MH, Goldsmith EJ. *Structure.* 1995; 3:299. [PubMed: 7540485]
110. Cohen P, Frame S. *Nat. Rev. Mol Cell Bio.* 2001; 2:769. [PubMed: 11584304]
111. Frame S, Cohen P. *Biochem. J.* 2001; 359:1. [PubMed: 11563964]
112. Joep RS, Johnson GV. *Trends Biochem. Sci.* 2004; 29:95. [PubMed: 15102436]
113. Cohen P, Goedert M. *Nat. Rev. Drug Discov.* 2004; 3:479. [PubMed: 15173837]
114. Dajani R, Fraser E, Roe SM, Yeo M, Good VM, Thompson V, Dale TC, Pearl LH. *EMBO J.* 2003; 22:494. [PubMed: 12554650]
115. Doble BW, Woodgett JR. *J. Cell Sci.* 2003; 116:1175. [PubMed: 12615961]
116. ter Haar E, Coll JT, Austen DA, Hsiao HM, Swenson L, Jain J. *Nat. Struct. Biol.* 2001; 8:593. [PubMed: 11427888]
117. Ali A, Hoeflich KP, Woodgett JR. *Chem. Rev.* 2001; 101:2527. [PubMed: 11749387]
118. Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, Okamura H, Woodgett J, He X. *Nature.* 2005; 438:873. [PubMed: 16341017]
119. Gui JF, Lane WS, Fu XD. *Nature.* 1994; 369:678. [PubMed: 8208298]
120. Aubol BE, Chakrabarti S, Ngo J, Shaffer J, Nolen B, Fu XD, Ghosh G, Adams JA. *P. Natl. Acad. Sci. USA.* 2003; 100:12601.
121. Colwill K, Feng LL, Yeakley JM, Gish GD, Caceres JF, Pawson T, Fu XD. *J. Biol. Chem.* 1996; 271:24569. [PubMed: 8798720]
122. Wang HY, Lin W, Dyck JA, Yeakley JM, Songyang Z, Cantley LC, Fu XD. *J. Cell Biol.* 1998; 140:737. [PubMed: 9472028]
123. Yun CY, Fu XD. *J. Cell Biol.* 2000; 150:707. [PubMed: 10952997]
124. Aubol BE, Nolen B, Vu D, Ghosh G, Adams JA. *Biochemistry.* 2002; 41:10002. [PubMed: 12146964]
125. Meggio F, Pinna LA. *FASEB J.* 2003; 17:349. [PubMed: 12631575]
126. Litchfield DW. *Biochem. J.* 2003; 369:1. [PubMed: 12396231]
127. Kemp BE, Pearson RB. *Method Enzymol.* 1991; 200:121.
128. Sarno S, Boldyreff B, Marin O, Guerra B, Meggio F, Issinger OG, Pinna LA. *Biochem. Biophys. Res. Com.* 1995; 206:171. [PubMed: 7818517]
129. Price MA. *Genes Dev.* 2006; 20:399. [PubMed: 16481469]
130. Hunter T, Plowman GD. *Trends Biochem. Sci.* 1997; 22:14.
131. Flotow H, Graves PR, Wang AQ, Fiol CJ, Roeske RW, Roach PJ. *J. Biol. Chem.* 1990; 265:14264. [PubMed: 2117608]
132. Marin O, Bustos VH, Cesaro L, Meggio F, Pagano MA, Antonelli M, Allende CC, Pinna LA, Allende JE. *P. Natl. Acad. Sci. U S A.* 2003; 100:10193.
133. Madhusudan, Trafny EA, Xuong NH, Adams JA, Ten Eyck LF, Taylor SS, Sowadski JM. *Protein Sci.* 1994; 3:176. [PubMed: 8003955]
134. Timm T, Li XY, Biernat J, Jiao J, Mandelkow E, Vandekerckhove J, Mandelkow EM. *EMBO J.* 2003; 22:5090. [PubMed: 14517247]
135. Huse M, Kuriyan J. *Cell.* 2002; 109:275. [PubMed: 12015977]
136. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, Regan J. *Nat. Struct. Biol.* 2002; 9:268. [PubMed: 11896401]
137. Jauch R, Jakel S, Netter C, Schreiter K, Aicher B, Jackie H, Wahl MC. *Structure.* 2005; 13:1559. [PubMed: 16216586]
138. Kallunki T, Su B, Tsigelny I, Sluss HK, Dérijard B, Moore G, Davis R, Karin M. *Genes Dev.* 1994; 8:2996. [PubMed: 8001819]
139. Kallunki T, Deng T, Hibi M, Karin M. *Cell.* 1996; 87:929. [PubMed: 8945519]
140. Bardwell L, Thorner J. *Trends Biochem. Sci.* 1996; 21:373. [PubMed: 8918190]

141. Jacobs D, Glossip D, Xing H, Muslin AJ, Kornfeld K. *Gene. Dev.* 1999; 13:163. [PubMed: 9925641]
142. Holland PM, Cooper JA. *Curr. Biol.* 1999; 9:R329. [PubMed: 10322109]
143. Tanoue T, Adachi M, Moriguchi T, Nishida E. *Nat. Cell Biol.* 2000; 2:110. [PubMed: 10655591]
144. Tanoue T, Nishida E. *Cell Signal.* 2003; 15:455. [PubMed: 12639708]
145. Sharrocks AD, Yang SH, Galanis A. *Trends Biochem. Sci.* 2000; 25:448. [PubMed: 10973059]
146. Enslen H, Davis RJ. *Biol Cell.* 2001; 93:5. [PubMed: 11730322]
147. Bogoyevitch MA, Kobe B. *Microbiol. Mol. Biol. Rev.* 2006; 70:1061. [PubMed: 17158707]
148. Gum RJ, Young PR. *Biochem. Biophys. Res. Commun.* 1999; 266:284. [PubMed: 10581204]
149. Zhou H, Zheng M, Chen J, Xie C, Kolatkar AR, Zarubin T, Ye Z, Akella R, Lin S, Goldsmith EJ, Han J. *Mol. Cell. Biol.* 2006; 26:3824. [PubMed: 16648477]
150. Zhang J, Zhou B, Zheng CF, Zhang ZY. *J. Biol. Chem.* 2003; 278:29901. [PubMed: 12754209]
151. Frodin M, Antal TL, Dummmler BA, Jensen CJ, Deak M, Gammeltoft S, Biondi RM. *EMBO J.* 2002; 21:5396. [PubMed: 12374740]
152. Balendran A, Biondi RM, Cheung PC, Casamayor A, Deak M, Alessi DR. *J. Biol. Chem.* 2000; 275:20806. [PubMed: 10764742]
153. Frodin M, Jensen CJ, Merienne K, Gammeltoft S. *Embo J.* 2000; 19:2924. [PubMed: 10856237]
154. Biondi RM, Cheung PC, Casamayor A, Deak M, Currie RA, Alessi DR. *EMBO J.* 2000; 19:979. [PubMed: 10698939]
155. Zheng J, Trafhy EA, Knighton DR, Xuong N-H, Taylor SS, Ten Eyck LF, Sowadski JM. *Acta Cryst.* 1993; D49:362.
156. Harper JW, Adams PD. *Chem. Rev.* 2001; 101:2511. [PubMed: 11749386]
157. Noble ME, Endicott JA, Brown NR, Johnson LN. *Trends Biochem. Sci.* 1997; 22:482. [PubMed: 9433129]
158. Chen J, Saha P, Kornbluth S, Dynlacht BD, Dutta A. *Mol. Cell. Biol.* 1996; 16:4673. [PubMed: 8756624]
159. Adams PD, Sellers WR, Sharma SK, Wu AD, Nalin CM, Kaelin WG Jr. *Mol. Cell. Biol.* 1996; 16:6623. [PubMed: 8943316]
160. Chothia C, Levitt M, Richardson D. *J. Mol. Biol.* 1981; 145:215. [PubMed: 7265198]
161. Schulman BA, Lindstrom DL, Harlow E. *P. Natl. Acad. Sci. U S A.* 1998; 95:10453.
162. Parang K, Till JH, Ablooglu AJ, Kohanski RA, Hubbard SR, Cole PA. *Nat. Struct. Biol.* 2001; 8:37. [PubMed: 11135668]
163. Stevenson-Lindert LM, Fowler P, Lew J. *J Biol Chem.* 2003; 278:50956. [PubMed: 14506259]
164. Lee T, Hoofnagle AN, Kabuyama Y, Stroud J, Min X, Goldsmith EJ, Chen L, Resing KA, Ahn NG. *Mol. Cell.* 2004; 14:43. [PubMed: 15068802]
165. Strajbl M, Shurki A, Warshel A. *P. Natl. Acad. Sci. USA.* 2003; 100:14834.
166. Goldsmith EJ. *FASEB J.* 1996; 10:702. [PubMed: 8635687]
167. Wang Z, Mottonen J, Goldsmith EJ. *Biochemistry.* 1996
168. Gao X, Harris TK. *J. Biol. Chem.* 2006; 281:21670. [PubMed: 16737971]
169. Jencks WP. *Methods Enzymol.* 1989; 171:145. [PubMed: 2531833]
170. Murphy LO, Blenis J. *Trends Biochem. Sci.* 2006; 31:268. [PubMed: 16603362]
171. Grewal S, Molina DM, Bardwell L. *Cell Signal.* 2006; 18:123. [PubMed: 15979847]

Figure 1.

a) Secondary structure of protein kinases based on PKA. Helices are cyan, β -strands magenta, and loops deep salmon, b) The MAP kinase docking groove, the AGC hydrophobic motif (HM) pocket, and CDK2 recruitment peptide docking groove and SR docking groove are in violet. The cyclin-A binding site on CDK2 is in gray. Figures generated using PyMOL (Delano Scientific, San Carlos, CA).

2a

Figure 2.

The P+1 specificity pocket of Ser/Thr protein kinases a). All atom stereoview of the P+1 specificity pocket of PKA (PDB file 1ATP), carbon in green, oxygen in red, nitrogen in blue, phosphorus in orange and sulfur in yellow, b) P+1 specificity pocket of PKA (PDB file 1ATP), c) PHK (2PHK), d) CDK2 (1QMZ), e) ERK2 (2ERK), and f) CK1 (1CSN). In Figures 2b–2f, carbon atoms of the bound peptide are light blue, the P+1 pocket and APE helix are yellow, the activation segment is green, the catalytic loop is magenta, and helix G is cyan. In Figures 2b–2f only the P+1 pocket, close by catalytic residues, and the activation segment phosphorylation site are shown rendered in ball-and-stick representation. Hydrogen bonds are shown in red dashed lines.

Figure 3.

Docking interactions between kinase and corresponding peptides with the kinase surface rendered in gray, otherwise the coloring scheme is the same as in Figure 1. a) ERK2 and docking peptide HePTP (2GPH). Carbon atoms of the peptide are blue. Note how the peptide helix orients the Arg20' and Arg21' toward the ERK2 acidic patch. b) PKA (1ATP). C-terminus of PKA in blue binds in the kinase HM pocket. Note how the reverse turn (at Thr348-Glu349) brings Phe347 and Phe350 close together. The side-chain of Thr348, which caps the helical turn, has been eliminated for clarity, c) CDK2 with recruitment peptide pi07 (1H28). Peptide, shown in blue, is bound in the hydrophobic crevice formed by kinase helices 1 and 3. d) Surface representation of pCDK2/cyclin-A with CDC6 bis-substrate inhibitor spanning active site and recruitment site. Visible residues shown in stick representation; disordered residues indicated by green balls. e) SRPK1 with docking peptide ASF/SF2 in blue (1WBP) showing arginine-mediated interactions.

Figure 4.

Peptide induced allostery in MAP kinases and AGC kinases. a) ERK2/pepHePTP (2GPH) superimposed with unphosphorylated unliganded ERK2 (1ERK). Note the very large changes in the activation segment, and changes in the N-terminus. b) PKB/GSK3 peptide (1O6K) superimposed with unphosphorylated PKB (1MRY). Helices B and C, as well as the activation segment become ordered in peptide-bound PKB. Unliganded conformations are rendered in cyan, and activation segment green. Peptide-bound structures are pink, activation segment red, and peptide yellow.

Table 1

Crystal structures of Ser/Thr Protein kinases

Group	Kinase	PDB	Organism	Ligation State	Phos. State	Activation State	Origin of Inactivity	Reference
AGC	PKA	1ATP	Mouse	MnATP and peptide	P	Active	-	a1
		1BKX	Mouse	Adenosine	P	Active	-	a2
		1CDK	Pig	PKI peptide	P	Inhibited	-	62
		1CTP	Pig	Inhibitor peptide	P	Inhibited	-	29
		1FMO	Mouse	PKI inhibitor and adenosine	P	Inhibited	-	a3
		1U7E	Mouse	AMPPNP, R-subunit (bovine)	P	Inhibited		27
		1J3H	Mouse	apo	P	Open	-	a4
		1JLU	Mouse	Substrate peptide	P	Active	-	133
		1L3R	Mouse	Transition state	P	Active	-	a5
		1MRV	Human	apo	U	Inactive	No helix C	33
		1MRY	Human	apo	U	Inactive	No helix C	33
		1O6K	Human	GSK3 peptide, AMPPNP	P	Active	-	31
		1O6L	Human	AMP-PNP, GSK3 peptide	P	Active	-	31
AGC	PKB	1GZK	Human	apo	U	Inactive	DFG Out, Thr	75
		1GZN	Human	apo	U	Inactive	DFG Out, Thr	75
		1GZO	Human	apo	U	Inactive	DFG Out, Thr	a6
		1ZRZ	Human	BIN-1 inhibitor	P	Active	-	a7
		1HIW	Human	ATP	P	Active	-	28
		1YM7	Bovine	Apo	U	Active	-	29
		2BCJ	Bovine	Ga, Gb subunits, GDP, AIF ₄ ⁻	U	Active	-	80
		2ACX	Human	AMPPNP, Mg	U	Active	-	79
		2C6D	Human	ADPNP	U	Active	-	a8
		1MUO	Human	Apo	U	Inactive	DFG Out	a9
		1OL5	Human	TPX-2 peptide	P	Active	-	77
		2BFX	Frog	Incenp peptide	P	Active	-	78
		2F2U	Bovine	Apo	U	Active	-	a10
AGC	ROCK							

Group	Kinase	PDB	Organism	Ligation State	Phos. State	Activation State	Origin of Inactivity	Reference
CAMK	CamK1	1A06	Rat	Apo	U	Autoinhibited	DFG Out, Thr	37
	CamK1 δ	2JC6	Human	Inhibitor	U	Inactive	Act loop, autoinhibited	To be published
	CamK1 γ	2JAM	Human	Inhibitor	U	Inactive	dimer	To be published
	ChKI	1IA8	Human	Apo	U	Active	-	a11
		1ZYS	Human	Inhibitor	U	Active	-	To be published
	DAPK	1IG1	Human	AMPPNP, Mn	U	Active	-	a12
		1JKS	Human	Apo	U	Active	-	a12
	DAPK2	1WMK	Human	Apo	U	Inactive	Dimerized	To be published
	DAPK3	1YRP	Human	Apo	U	Inactive	Dimerized	To be published
		2J90	Human	IAK-Inhibitor	P	Active	-	To be published
	Twitchin	1KOA	C.elegans	Apo	U	Autoinhibited	-	35
		1KOB	Aplysia	Apo	U	Autoinhibited	-	a13
	MAPKAP-K2	1KWP	Human	Apo	U	Autoinhibited	-	a14
		1NY3	Human	ADP	U	Active	-	a15
	PHK	1PHK	Rabbit	MnATP	U	Active	-	38
		2PHK	Rabbit	Phosphorylase peptide, MnATP	U	Active	-	39
	Titin	1TKI	Human	Apo	U	Autoinhibited	-	36
	MSKI	1VZO	Human	Apo	U	Autoinhibited	-	a16
		1XR1	Human	AMP-PNP	U	Active	-	a17
		1XWS	Human	Inhibitor	U	Active	-	to be published
	Pim-1	1YWV	Human	Apo	U	Active	-	a18
		1YXT	Human	AMPPNP	U	Active	-	a18
		2BIL	Human	Pin1 peptide	U	Active	-	To be published
		2BIK	Human	BIM-1 inhibitor	P	Active	-	To be published
	MARK	1ZMU	Rat	Apo	U	Inactive	DFG Out, Thr	a19
	MNK1	2HW6	Human	Apo	U	Inactive	DFG Out, Thr	a20
	MNK2	2AC3	Human	Apo	U	Inactive	DFG Out, Thr	137
	CamKII	2BDW	C.elegans	apo	U	Autoinhibited	-	a21
	SNF1	2FH9	Yeast	Apo	U	Inactive	Thr	a22

Group	Kinase	PDB	Organism	Ligation State	Phos. State	Activation State	Origin of Inactivity	Reference
CMGC	Amp-Activated	2H6D	Human	apo	U	Inactive	DFG Out, Thr	To be published
		1B38	Human	ATP	U	Inactive	Thr	40
	CDK2	1B39	Human	ATP	U	Inactive	Thr	40
		1BUH	Human	CKSHS1	U	Inactive	No helix C	a23
		1CKP	Human	Inhibitor	U	Inactive	Thr	a24
		1FIN	Human	ATP	U	Inactive	Act loop	a25
		1FQI	Human	KAP, ATP	P	Inactive	Thr, KAP	a26
		1HCK	Human	Mg ATP	U	Inactive	Thr	a27
		1HCL	Human	Apo	U	Inactive	Thr	a28
		1JST	Human	Cyclin-A and ATP	P	Active	-	42
		1PW2	Human	Apo	U	Inactive	Thr	a29
		1H27	Human	P27 peptide	P	Active	-	63
		1H28	Human	P107 peptide	P	Active	-	63
		2CCI	Human	CDC6 peptide	P	Active	-	67
	CDK5	1H4L	Human	fragment of p35 activator	U	Active	-	a30
	CDK6	1B17	Human	P16INK4A	U	Inactive	No helix C	a31
		1B18	Human	P19INK4D	U	Inactive	No helix C	a31
	CDK7	1JOW	Human	Viral cyclin	U	Active	-	a32
		1UA2	Human	ATP	U	Inactive	Thr	a33
	p38	1CM8	Human	AMPPNP	P	Active	-	45
		1P38	Mouse	apo	U	Inactive	Thr	44
		1LEW	Mouse	MEF2 peptide	U	Inactive	Thr	68
		1LEZ	Mouse	MKK3B peptide	U	Inactive	Thr	68
		1WFC	Human	Apo	U	Inactive	Thr	a34
ERK2		1R39	Human	Apo	U	Inactive	Thr	a35
		1ERK	Rat	Apo	U	Inactive	Act loop	43
		2ERK	Rat	Apo	P	Active	-	28
		2GPH	Rat	HeTP peptide	U	Inactive	Thr	70
		2FYS	Rat	MKP3 peptide	U	Inactive	Thr	71

Group	Kinase	PDB	Organism	Ligation State	Phos. State	Activation State	Origin of Inactivity	Reference
	ERK3	2I6L	Human	Apo	U	Inactive	Thr	To be published
	JNK1	1UKH	Human	JIP peptide	U	Inactive	Thr	69
	JNK3	1JNK	Human	ANP	U	Inactive	Thr	46
	GSK3	1H8F	Human	Inhibitor	U	Active	-	13
		1O9U	Human	Axin peptide, Inhibitor	P	Active	-	114
		1GNG	Human	FRATtide	P	Active	-	19
		1JWH	Human	Apo	U	Active	-	23
	CK2	1ILP4	Maize	Mg AMPPNP	U	Active	-	a36
		1NA7	Human	APO	U	Active	-	a37
		1PIK	Human	AMPPNP	U	Active	-	a38
		1DAW	Maize	MgAMPPNP	U	Inactive	Thr	47
		1DAY	Maize	MgGMPNP	U	Inactive	Thr	47
		1DS5	Maize	AMP	U	Inactive	Dimerized	a39
	Sky1P	1HOW	Yeast	Apo	U	Active	-	49
		1Q8Y	Yeast	ADP	U	Active	-	a40
		1Q97	Yeast	ATP	U	Active	-	a40
		2A1A	Yeast	EIF2 α ,	P	Inactive	Thr	50
	PKR	2A19	Yeast	EIF2 α , AMPPNP	P	Inactive	Thr	50
		2B9F	Yeast	MgADP	U	Inactive	Thr	51
	FUS3	2B9J	Yeast	FAR1 peptide, MgADP	U	Inactive	Thr	51
		2F49	Yeast	Ste5 peptide	U	Inactive	Thr	72
	CLK1	1Z57	Human	Hymenialdsine	U	Active	-	To be published
	CLK3	2EU9	Human	Apo	U	Active	-	To be published
		2EXE	Human	Apo	U	Fragment	-	To be published
	SRPK1	1WBP	Human	ASF/SF2 peptide, ADP	U	Active	-	73
	PAK1	1F3M	Human	Apo	U	Autoinhibited	-	24
		1YHW	Human	Apo K299R	U	Active	-	55
STE	PAK4	2BVA	Human	Apo	P	Active	-	To be published
		2J01	Human	Apo	P	Active	-	To be published

Group	Kinase	PDB	Organism	Ligation State	Phos. State	Activation State	Origin of Inactivity	Reference
CKI	PAK5	2F57	Human	Apo	P	Active	-	To be published
	PAK6	2C30	Human	Apo	P	Active	-	To be published
	MEK1	1S9J	Human	MgATP, Inhibitor	U	Inactive	Act loop, Thr	<i>a41</i>
	MEK2	1S9I	Human	MgATP, Inhibitor	U	Inactive	Act loop Thr	<i>a41</i>
	MEKK5	2CLQ	Human	inhibitor	U	Active	-	To be published
	TAO2	1U5Q	Rat	Apo	P	Active	-	54
		1U5R	Rat	Mg ATP	P	Active	-	54
	GCN2	1ZYC	Yeast	Apo	U	Inactive	Thr	<i>a42</i>
		1ZYD	Yeast	ATP	U	Inactive	Thr	<i>a42</i>
	TAK1	2EVA	Human	TAB1	U	Inactive	Thr, DFG out	81
	SLK	2J51	Human	Inhibitor	U	Inactive	Thr, dimer	To be published
	SLK	2JFL	Human	K0056 inhibitor	P	Inactive	dimer	To be published
	STK10	2J7T	Human	SU11274 inhibitor	U	Inactive	dimer	To be published
	CK1	2CSN	Yeast	CK17 inhibitor	U	?	Thr ?	<i>a43</i>
	CK1	1CSN	Yeast	MgATP	U	?	Thr?	52
	CK1 γ 1	2CMW	Human	Purine class Inhibitor	U	?	?	To be published
	CK1 γ 2	2C47	Human	Inhibitor	U	Inactive	Act loop, dimer	To be published
	CK1 γ 3	2CHL	Human	Inhibitor	U	?	Thr?	To be published
	CK1 γ 3	2IZR	Human	inhibitor	U	Active ?	Thr ?-	To be published
	CK1 δ	1CK1	Rat	Apo	U	Active	-	<i>a44</i>
TKL	TGF β TGF β	1B6C 1PY5	Human Human	FKBP12 Inhibitor	U U	Inactive Inactive	Act loop Act loop	57 <i>a45</i>
	B-Raf	1UWH	Human	Inhibitor	U	Inactive	Act loop	56
	IRAK-4	2NRY	Human	Staurosporine	P	Active	-	<i>a46</i>
	pK α B	1MRU	Bacteria	ATP- γ s	U	Inactive	Thr	60
OTHER		1O6Y	Bacteria	MgAMPPCP	U	Inactive	Thr	<i>a47</i>
	pK α E	2H34	Bacteria	apo	U	Inactive	Thr, DFG-out	<i>a48</i>
	WNK1	1T4H	Rat	Apo	U	Inactive	Thr, Act loop	59
	WEE1A	1X8B	Human	Inhibitor	U	Active	-	<i>a49</i>

Group	Kinase	PDB	Organism	Ligation State	Phos. State	Activation State	Origin of Inactivity	Reference
	STK16	2BUJ	Human	Staurosporine	U	?	?	To be published
	NEK2	2CL1	Human	Pyrrole Indolinone	U	Inactive	Thr, DFG-out	To be published

The designations for origin of inactivity are DFF-Out, if the conserved DFG is displaced from the active conformation, Thr refers to displacement of Thr201 or homologous residue, and Act loop refers to other displacements of the activation loop, but not Thr201. Dimer is used when dimerization has contributed to inactivity, and “?” is used where some ambiguity is present. The table is available at <http://www.hhmi.swmed.edu/Labs/bg/Kinase>

- (a1) Zheng, J.; Trafny, E. A.; Knighton, D. R.; Xuong, N.-H.; Taylor, S. S.; Ten Eyck, L. F.; Sowadski, J. M. *Acta Cryst.* **1993**, D49, 362.
- (a2) Narayana, N.; Cox, S.; Nguyen-huu, X.; Ten Eyck, L. F.; Taylor, S. S. *Struct* **1997**, 5, 921.
- (a3) Narayana, N.; Cox, S.; Shaltiel, S.; Taylor, S. S.; Xuong, N. *Biochem* **1997**, 36, 4438.
- (a4) Akamine, P.; Madhusudan; Wu, J.; Xuong, N. H.; Ten Eyck, L. F.; Taylor, S. S. *J Mol Biol* **2003**, 327, 159.
- (a5) Madhusudan; Akamine, P.; Xuong, N. H.; Taylor, S. S. *Nat Struct Biol* **2002**, 9, 273.
- (a6) Yang, J.; Cron, P.; Thompson, V.; Good, V. M.; Hess, D.; Hemmings, B. A.; Barford, D. *Mol Cell* **2002**, 9, 1227.
- (a7) Messerschmidt, A.; Macieira, S.; Velarde, M.; Badeker, M.; Benda, C.; Jestel, A.; Brandstetter, H.; Neufeld, T.; Blaesse, M. *J Mol Biol* **2005**, 352, 918.
- (a8) Heron, N. M.; Anderson, M.; Blowers, D. P.; Breed, J.; Eden, J. M.; Green, S.; Hill, G. B.; Johnson, T.; Jung, F. H.; McMiken, H. H.; Mortlock, A. A.; Pannifer, A. D.; Paupit, R. A.; Pink, J.; Roberts, N. J.; Rowsell, S. *Bioorg Med Chem Lett* **2006**, 16, 1320.
- (a9) Cheetham, G. M.; Knegetel, R. M.; Coll, J. T.; Renwick, S. B.; Swenson, L.; Weber, P.; Lippke, J. A.; Austen, D. A. *J Biol Chem* **2002**, 277, 42419.
- (a10) Yamaguchi, H.; Kasa, M.; Amano, M.; Kaibuchi, K.; Hakoshima, T. *Struct* **2006**, 14, 589.
- (a11) Chen, P.; Luo, C.; Deng, Y.; Ryan, K.; Register, J.; Margosiak, S.; Tempczyk-Russell, A.; Nguyen, B.; Myers, P.; Lundgren, K.; Kan, C. C.; O'Connor, P. M. *Cell* **2000**, 100, 681.
- (a12) Tereshko, V.; Teplova, M.; Brunzelle, J.; Watterson, D. M.; Egli, M. *Nat Struct Biol* **2001**, 8, 899.
- (a13) Kobe, B.; Heierhorst, J.; Feil, S. C.; Parker, M. W.; Benian, G. M.; Weiss, K. R.; Kemp, B. E. *Embo J* **1996**, 15, 6810.
- (a14) Meng, W.; Swenson, L. L.; Fitzgibbon, M. J.; Hayakawa, K.; Ter Haar, E.; Behrens, A. E.; Fulghum, J. R.; Lippke, J. A. *J Biol Chem* **2002**, 277, 37401.
- (a15) Underwood, K. W.; Parris, K. D.; Federico, E.; Mosyak, L.; Czerwinski, R. M.; Shane, T.; Taylor, M.; Svenson, K.; Liu, Y.; Hsiao, C. L.; Wolfson, S.; Maguire, M.; Malakian, K.; Telliez, J. B.; Lin, L. L.; Kriz, R. W.; Seehra, J.; Somers, W. S.; Stahl, M. L. *Struct* **2003**, 11, 627.
- (a16) Smith, K. J.; Carter, P. S.; Bridges, A.; Horrocks, P.; Lewis, C.; Pettman, G.; Clarke, A.; Brown, M.; Hughes, J.; Wilkinson, M.; Bax, B.; Reith, A. *Struct* **2004**, 12, 1067.
- (a17) Qian, K. C.; Wang, L.; Hickey, E. R.; Studts, J.; Barringer, K.; Peng, C.; Kronkaitis, A.; Li, J.; White, A.; Mische, S.; Farmer, B. *J Biol Chem* **2005**, 280, 6130.
- (a18) Kumar, A.; Mandiyan, V.; Suzuki, Y.; Zhang, C.; Rice, J.; Tsai, J.; Artis, D. R.; Ibrahim, P.; Bremer, R. *J Mol Biol* **2005**, 348, 183.

- (a19) Panneerselvam, S.; Marx, A.; Mandelkow, E. M.; Mandelkow, E. *Struct* **2006**, *14*, 173.
- (a20) Jauch, R.; Cho, M. K.; Jakel, S.; Netter, C.; Schreiter, K.; Aicher, B.; Zweckstetter, M.; Jackie, H.; Wahl, M. C. *Embo J* **2006**, *25*, 4020.
- (a21) Rosenberg, O. S.; Deindl, S.; Sung, R. J.; Naim, A. C.; Kuriyan, J. *Cell* **2005**, *123*, 849.
- (a22) Nayak, V.; Zhao, K.; Wyce, A.; Schwartz, M. F.; Lo, W. S.; Berger, S. L.; Marmorstein, R. *Struct* **2006**, *14*, 477.
- (a23) Bourne, Y.; Watson, M. H.; Hickey, M. J.; Holmes, W.; Rocque, W.; Reed, S. I.; Tainer, J. A. *Cell* **1996**, *84*, 863.
- (a24) Gray, N. S.; Wodicka, L.; Thunnissen, A. M.; Norman, T. C.; Kwon, S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S. H.; Lockhart, D. J.; Schultz, P. G. *Science* **1998**, *281*, 533.
- (a25) Jeffrey, P. D.; Russo, A. A.; Polyak, K.; Gibbs, E.; Hurwitz, J.; Massagué, J.; Pavletich, N. P. *Nature* **1995**, *376*, 313.
- (a26) Song, H.; Hanlon, N.; Brown, N. R.; Noble, M. E.; Johnson, L. N.; Barford, D. *Mol Cell* **2001**, *7*, 615.
- (a27) Schulze-Gahmen, U.; De Bondt, H. L.; Kim, S. H. *J Med Chem* **1996**, *39*, 4540.
- (a28) Schulze-Gahmen, U.; Brandsen, J.; Jones, H. D.; Morgan, D. O.; Meijer, L.; Vesely, J.; Kim, S.-H. *PROTEINS: Structure, Function, and Genetics* **1995**, *22*, 378.
- (a29) Wu, S. Y.; McNae, I.; Kontopidis, G.; McClue, S. J.; Melmes, C.; Stewart, K. J.; Wang, S.; Zheleva, D. I.; Marriage, P.; Taylor, P.; Fischer, P. M.; Walkinshaw, M. D. *Struct* **2003**, *11*, 399.
- (a30) Turrione, C.; Dhavan, R.; Peng, J.; Areces, L. B.; Tsai, L. K.; Musacchio, A. *Mol Cell* **2001**, *8*, 657.
- (a31) Russo, A. A.; Tong, L.; Lee, J. O.; Jeffrey, P. D.; Pavletich, N. P. *Nature* **1998**, *395*, 237.
- (a32) Schulze-Gahmen, U.; Kim, S. H. *Nat Struct Biol* **2002**, *9*, 177.
- (a33) Lolli, G.; Lowe, E. D.; Brown, N. R.; Johnson, L. N. *Struct* **2004**, *12*, 2067.
- (a34) Wilson, K. P.; Fitzgibbon, M. J.; Caron, P. R.; Griffith, J. P.; Chen, W. Y.; McCaffrey, P. G.; Chambers, S. P.; Su, M. S.-S. *The J of Biol Chem* **1996**, *271*, 27696.
- (a35) Patel, S. B.; Cameron, P. M.; Frantz-Wattley, B.; O'Neill, E.; Becker, J. W.; Scapin, G. *Biochim Biophys Acta* **2004**, *1696*, 67.
- (a36) Yde, C. W.; Ernakova, I.; Issinger, O. G.; Niefind, K. *J Mol Biol* **2005**, *347*, 399.
- (a37) Pechkova, E.; Zanotti, G.; Nicolini, C. *Acta Crystallogr D Biol Crystallogr* **2003**, *59*, 2133.
- (a38) Ernakova, I.; Boldyreff, B.; Issinger, O. G.; Niefind, K. *J Mol Biol* **2003**, *330*, 925.
- (a39) Battistutta, R.; Samo, S.; De Moliner, E.; Marin, O.; Issinger, O. G.; Zanotti, G.; Pinna, L. A. *Eur J Biochem* **2000**, *267*, 5184.
- (a40) Nolen, B.; Ngo, J.; Chakrabarti, S.; Vu, D.; Adams, J. A.; Ghosh, G. *Biochem* **2003**, *42*, 9575.
- (a41) Ohren, J. F.; Chen, H.; Pavlovsky, A.; Whitehead, C.; Zhang, E.; Kuffia, P.; Yan, C.; McConnell, P.; Spessard, C.; Banotai, C.; Mueller, W. T.; Delaney, A.; Omer, C.; Sebolt-Leopold, J.; Dudley, D. T.; Leung, I. K.; Flamme, C.; Warmus, J.; Kaufman, M.; Barrett, S.; Tecle, H.; Hasemann, C. A. *Nat Struct Mol Biol* **2004**, *11*, 1192.
- (a42) Padyana, A. K.; Qiu, H.; Roll-Mecak, A.; Hinnebusch, A. G.; Burley, S. K. *J Biol Chem* **2005**, *280*, 29289.

- (a43) Xu, R.-M.; Carmel, G.; Kuret, J.; Cheng, X. *Proc. Natl. Acad. Sci.* **1996**, *93*, 6308.
- (a44) Longenecker, K. L.; Roach, P. J.; Hurley, T. D. *The J Mol Biol* **1996**, *257*, 618.
- (a45) Sawyer, J. S.; Beight, D. W.; Britt, K. S.; Anderson, B. D.; Campbell, R. M.; Goodson, T., Jr.; Herron, D. K.; Li, H. Y.; McMillen, W. T.; Mort, N.; Parsons, S.; Smith, E. C.; Wagner, J. R.; Yan, L.; Zhang, F.; Yingling, J. M. *Bioorg Med Chem Lett* **2004**, *14*, 3581.
- (a46) Wang, Z.; Liu, J.; Sudom, A.; Ayres, M.; Li, S.; Wesche, H.; Powers, J.P.; Walker, N. P. *Struct.* **2006**, *14*, 1835.
- (a47) Ortiz-Lombardia, M.; Pompeo, F.; Boitel, B.; Alzari, P.M. *J Biol Chem* **2003**, *278*, 13094.
- (a48) Gay, L. M.; Ng, H. L.; Alber, T. *J Mol Biol* **2006**, *360*, 409.
- (a49) Squire, C. J.; Dickson, J. M.; Ivanovic, I.; Baker, E. N. *Struct* **2005**, *13*, 541.

Table 2

Crystal structures of protein kinases in complex with substrate and other peptides

Group	Kinase	PDB	Complex	Reference
AGC	PKA	1ATP 1CDK	PKI peptide PKI peptide	27,61 62
	PKB	1O6K	GSK3 peptide	31
	Aurora	1OL5	TPX-2 peptide	77
	Aurora	2BFX	Incenp peptide	78
CAMK	PHK	2PHK	Phosphorylase peptide	39
	Pim-1	2BIL	Pimtide peptide	To be published
CMGC	CDK2	1JST	Cyclin-A	42
		1H28	P107 peptide	63
		1H27	P27 peptide	63
		2CCI	CDC6 Peptide	67
	P38	1LEW 1LEZ	MEF2A peptide MKK3b peptide	68 68
	ERK2	2FYS 2GPH	MKP-3 peptide HePTP peptide	71 70
	JNK1	1UKH	JIP peptide	69
	GSK3	1GNG 1O9U	FRATtide Axin peptide	17 114
	FUS3	2B9J 2F49	FAR1 peptide Ste5 peptide	51 72
Other	PKR	2A1A	eIF2	50

Table 3

Activation loop and P+1 sites of Ser/Thr protein kinases

		<div style="display: flex; align-items: center; justify-content: center;"> <div style="border-top: 1px solid black; width: 100px; height: 2px;"></div> <div style="margin: 0 10px;">P+1</div> <div style="border-top: 1px solid black; width: 100px; height: 2px;"></div> </div>	
		Activation loop	
AGC	PKA	-180 IQVT <u>DFG</u> FAKR-V----K----GR-TWTL <u>CGTPEYL</u> AP <u>EIIL</u> -----SKGYNKAVDWW ²³²	
	PKB	-289 IKIT <u>DFGLCKE</u> GISD--G----AT-MKT <u>FCGTPEYL</u> AP <u>EVLE</u> -----DNDYGRAVDWW ³³⁴	
	pdk1	-219 IQIT <u>DFGTAKVLS</u> PESKQ---AR-ANS <u>FVGTAQYV</u> SP <u>ELLT</u> -----EKSACKSSDLW ²⁶⁷	
STE	TAO2	-165 VKLG <u>DFGS</u> ASIMAPA-----NSFV <u>GTPYWM</u> AP <u>EVILAM</u> D---EGQYDGKVDW ²⁰⁹	
	PAK1	-403 VKLT <u>DFGFCAQIT</u> PEQS-----KRST <u>TMVGTPYWM</u> AP <u>EVVTRK</u> -----AYGPKVDIW ⁴⁴⁸	
CAMK	PHK	-164 IKLT <u>DFGFS</u> CQLDPGE-----KLREVC <u>GTPSYL</u> AP <u>EII</u> EC <u>SMNDNH</u> PGYKGEVDMW ²¹⁴	
	CAMK	-158 IMIS <u>DFGLSKM</u> EDPGS-----VLSTAC <u>GTPGYV</u> AP <u>EVLA</u> -----QKPYSKAVDCW ²⁰²	
	Twitchin	-5287 LKLID <u>FG</u> LTAHLDPKQ-----SVKVT <u>TGTAEFA</u> AP <u>EVAE</u> -----GKPVGYITDMW ⁵³³²	
	MNK2	-222 VKIC <u>DFDLGSGIK</u> LNDCSPIS <u>TELLTPCGS</u> AEYMA <u>PEVVEAF</u> SEEA-SIYDKRCDLW ²⁷⁹	
CMGC	ERK2	-161 LKIC <u>DFGLARVAD</u> PDHDH---TGFLTEYVATRWYRA <u>PEIM</u> LNS----KGYTKSIDIW ²¹⁰	
	p38	-164 LKIL <u>DFGLARHTD</u> DE-----MTGYVATRWYRA <u>PEIM</u> LNW----MHYNQTVDIW ²⁰⁷	
	JNK	-203 LKIL <u>DFGLARTAG</u> TSF-----MTPYV <u>TRY</u> YRA <u>PEVILG</u> -----MGYKENVDIW ²⁴⁷	
	CDK2	-141 IKLA <u>DFGLARAFG</u> VPV-----RTYTHEVVT <u>LWYRAPEILLGC</u> -----KYYSTAVDIW ¹⁸⁷	
CKI	CK1	-145 VYIID <u>FG</u> LAKKYRDARTHQHIPYRENK <u>NLTGTARYASIN</u> THL-----GIEQSRRDDLE ¹⁷⁷	
	CKI	-150 IYVV <u>DFGMV</u> KFYRDPVTKQHIPYREKK <u>NLSGTARYMSIN</u> THL-----GREQSRRDDLE ²⁰²	
Other	Wnk1	-475 VKIG <u>DLGLATL</u> -K----R---ASFAKAVIGT <u>PEFMAPEMYE</u> -----EK-YDESVDYY ⁵¹⁷	

Sequences between the underlined residues are remodeled in inactive structures. Residues in the P+1 pocket and APE helix are green, the conserved threonine is red, the conserved glycine is cyan, and its replacement in CMGC kinases dark blue, the conserved hydrophobic residue at the bottom of the P+1 pocket is lavender, and its replacement in CMGC kinases magenta.

Table 4**Docking Peptide Motifs**

a) Docking site peptides for MAPK	
HePTP	RLQERRGSNVALMLDV
ELK1	PQKGRKPRDLELPLSP
MEK2	MKARRKPVLALTINP
b) Recruitment Peptide Motifs for CDKs	
p27	KPSACRNLFGP
p53	STSRHKKLMFK
p107	AGSAKRRLFGE
pRB	PPKPLKKLRFD
c) Hydrophobic Motifs for AGC kinases	
PKA	EKCGKE-FTEF
PKB	DSERRPHFPQFSYSTA
PRK2	EEEQEM-FRDFDYIADWC